Records
Every government record, registry entry, journal paper and filing we have checked, in one list. Filter by peptide or type. Each row says what the record says, what we could not confirm, and the day we opened it.
391 records. Filters need JavaScript.
- HHS draft policy pausing enforcement on six compounded peptides (Federal Register)
Status: Draft policy; comments open until Nov 14, 2026. LL-37 is not one of the six peptides the policy covers, per the policy appendix.
Caveat: Draft policy. The notice itself does not name the peptides; its appendix names six: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. We read the appendix through a text extraction, not the original PDF layout.
Verified Oct 31, 2026
- HHS draft 503A enforcement discretion policy appendix: covered peptides (checked for Oxytocin)
Status: Not covered. The covered list names BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. Oxytocin is not named.
Caveat: Read through a text extraction, not the original PDF layout. Draft policy; not binding.
Verified Nov 2, 2026
- HHS draft 503A enforcement discretion policy appendix: covered peptides (checked for Pinealon)
Status: Not covered. The covered list names BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. Pinealon is not named.
Caveat: Read through a text extraction, not the original PDF layout. Draft policy; not binding.
Verified Nov 2, 2026
- HHS draft 503A enforcement discretion policy appendix: covered peptides (checked for Thymalin)
Status: Not covered. The covered list names BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. Thymalin is not named.
Caveat: Read through a text extraction, not the original PDF layout. Draft policy; not binding.
Verified Nov 2, 2026
- HHS draft 503A enforcement discretion policy appendix: covered peptides (checked for Hexarelin)
Status: Not covered. The covered list names BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. Hexarelin is not named.
Caveat: Read through a text extraction, not the original PDF layout. Draft policy; not binding.
Verified Nov 2, 2026
- HHS draft 503A enforcement discretion policy appendix: covered peptides (checked for PT-141)
Status: Not covered. The covered list names BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. PT-141 is not named.
Caveat: Read through a text extraction, not the original PDF layout. Draft policy; not binding.
Verified Nov 2, 2026
- HHS draft policy pausing enforcement on six compounded peptides (Federal Register)
Status: Draft policy; comments open until Nov 14, 2026. State-licensed pharmacies, federal facilities and licensed physicians would not face enforcement for compounding the listed peptides, under conditions including a patient-specific prescription and quality testing. Not FDA approval. HHS says it may revisit the policy if a safety or quality problem arises.
Caveat: Draft and nonbinding. Six peptides covered; this record applies to each of them.
Verified Oct 31, 2026
- Public comment docket HHS-OASH-2026-0496
Status: Comments open until Nov 14, 2026. Docket for the HHS draft enforcement policy on compounded peptides.
Caveat: Not re-opened in the latest check (automated access blocked). The dossier links it without a summary.
Verified Oct 31, 2026
- HHS draft policy pausing enforcement on six compounded peptides (Federal Register)
Status: Draft policy; comments open until Nov 14, 2026. State-licensed pharmacies, federal facilities and licensed physicians would not face enforcement for compounding the listed peptides, under conditions including a patient-specific prescription and quality testing. Not FDA approval. HHS says it may revisit the policy if a safety or quality problem arises.
Caveat: Draft and nonbinding. Six peptides covered; this record applies to each of them.
Verified Oct 31, 2026
- Public comment docket HHS-OASH-2026-0496
Status: Comments open until Nov 14, 2026. Docket for the HHS draft enforcement policy on compounded peptides.
Caveat: Not re-opened in the latest check (automated access blocked). The dossier links it without a summary.
Verified Oct 31, 2026
- HHS draft 503A enforcement discretion policy appendix: covered peptides (checked for Tesamorelin)
Status: Not covered. The covered list names BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. Tesamorelin is not named.
Caveat: Read through a text extraction, not the original PDF layout. Draft policy; not binding.
Verified Nov 1, 2026
- HHS draft 503A enforcement discretion policy appendix: covered peptides (checked for Sermorelin)
Status: Not covered. The covered list names BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. Sermorelin is not named.
Caveat: Read through a text extraction, not the original PDF layout. Draft policy; not binding.
Verified Nov 1, 2026
- HHS draft 503A enforcement discretion policy appendix: covered peptides (checked for Kisspeptin-10)
Status: Not covered. The covered list names BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. Kisspeptin-10 is not named.
Caveat: Read through a text extraction, not the original PDF layout. Draft policy; not binding.
Verified Nov 1, 2026
- HHS draft 503A enforcement discretion policy appendix: covered peptides (checked for Ibutamoren)
Status: Not covered. The covered list names BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. Ibutamoren is not named.
Caveat: Read through a text extraction, not the original PDF layout. Draft policy; not binding.
Verified Nov 1, 2026
- HHS draft 503A enforcement discretion policy appendix: covered peptides (checked for GHRP-6)
Status: Not covered. The covered list names BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. GHRP-6 is not named.
Caveat: Read through a text extraction, not the original PDF layout. Draft policy; not binding.
Verified Nov 1, 2026
- HHS draft 503A enforcement discretion policy appendix: covered peptides (checked for Thymosin alpha-1)
Status: Not covered. The covered list names BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. Thymosin alpha-1 is not named.
Caveat: Read through a text extraction, not the original PDF layout. Draft policy; not binding.
Verified Nov 1, 2026
- Public comment docket HHS-OASH-2026-0496
Status: Comments open until Nov 14, 2026. Docket for the HHS draft enforcement policy on compounded peptides.
Caveat: Not re-opened in the latest check (automated access blocked).
Verified Oct 31, 2026
- Public comment docket HHS-OASH-2026-0496
Status: Comments open until Nov 14, 2026. Docket for the HHS draft enforcement policy on compounded peptides.
Caveat: Not re-opened in the latest check (automated access blocked).
Verified Oct 31, 2026
- HHS draft 503A enforcement discretion policy appendix: covered peptides (checked for AOD-9604)
Status: Not covered. The covered list names BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. AOD-9604 is not named.
Caveat: Read through a text extraction, not the original PDF layout. Draft policy; not binding.
Verified Nov 1, 2026
- Public comment docket HHS-OASH-2026-0496
Status: Comments open until Nov 14, 2026. Docket for the HHS draft enforcement policy on compounded peptides.
Caveat: Not re-opened in the latest check (automated access blocked).
Verified Oct 31, 2026
- HHS draft policy pausing enforcement on six compounded peptides (Federal Register)
Status: Draft policy; comments open until Nov 14, 2026. State-licensed pharmacies, federal facilities and licensed physicians would not face enforcement for compounding the listed peptides, under conditions including a patient-specific prescription and quality testing. Not FDA approval.
Caveat: Draft policy. The notice itself does not name the peptides; its appendix does. We read the appendix through a text extraction, not the original PDF layout.
Verified Oct 31, 2026
- HHS draft policy pausing enforcement on six compounded peptides (Federal Register)
Status: Draft policy; comments open until Nov 14, 2026. State-licensed pharmacies, federal facilities and licensed physicians would not face enforcement for compounding the listed peptides, under conditions including a patient-specific prescription and quality testing. Not FDA approval.
Caveat: Draft policy. The notice itself does not name the peptides; its appendix does. We read the appendix through a text extraction, not the original PDF layout.
Verified Oct 31, 2026
- Public comment docket HHS-OASH-2026-0496
Status: Comments open until Nov 14, 2026. Docket for the HHS draft enforcement policy on compounded peptides.
Caveat: Not re-opened in the latest check (automated access blocked).
Verified Oct 31, 2026
- HHS draft 503A enforcement discretion policy appendix: covered peptides (checked for GHRP-2)
Status: Not covered. The covered list names BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. GHRP-2 is not named.
Caveat: Read through a text extraction, not the original PDF layout. Draft policy; not binding.
Verified Nov 1, 2026
- HHS draft policy pausing enforcement on six compounded peptides (Federal Register)
Status: Draft policy; comments open until Nov 14, 2026. State-licensed pharmacies, federal facilities and licensed physicians would not face enforcement for compounding the listed peptides, under conditions including a patient-specific prescription and quality testing. Not FDA approval.
Caveat: Draft policy. The notice itself does not name the peptides; its appendix does. We read the appendix through a text extraction, not the original PDF layout.
Verified Oct 31, 2026
- HHS draft policy pausing enforcement on six compounded peptides (Federal Register)
Status: Draft policy; comments open until Nov 14, 2026. State-licensed pharmacies, federal facilities and licensed physicians would not face enforcement for compounding the listed peptides, under conditions including a patient-specific prescription and quality testing. Not FDA approval.
Caveat: Draft policy. The notice itself does not name the peptides; its appendix does. We read the appendix through a text extraction, not the original PDF layout.
Verified Oct 31, 2026
- HHS draft 503A enforcement discretion policy appendix: covered peptides (checked for Selank)
Status: Not covered. The covered list names BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. Selank is not named.
Caveat: Read through a text extraction, not the original PDF layout. Draft policy; not binding.
Verified Nov 1, 2026
- HHS draft policy pausing enforcement on six compounded peptides (Federal Register)
Status: Draft policy; comments open until Nov 14, 2026. Emideltide is not one of the six peptides the policy covers, per the policy appendix.
Caveat: Draft policy. The notice itself does not name the peptides; its appendix names six: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. We read the appendix through a text extraction, not the original PDF layout.
Verified Oct 31, 2026
- HHS draft 503A enforcement discretion policy appendix: covered peptides (checked for Ipamorelin)
Status: Not covered. The covered list names BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. Ipamorelin is not named.
Caveat: Read through a text extraction, not the original PDF layout. Draft policy; not binding.
Verified Nov 1, 2026
- HHS draft policy pausing enforcement on six compounded peptides (Federal Register)
Status: Draft policy; comments open until Nov 14, 2026. PEG-MGF is not one of the six peptides the policy covers, per the policy appendix.
Caveat: Draft policy. The notice itself does not name the peptides; its appendix names six: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. We read the appendix through a text extraction, not the original PDF layout.
Verified Oct 31, 2026
- HHS draft policy pausing enforcement on six compounded peptides (Federal Register)
Status: Draft policy; comments open until Nov 14, 2026. Melanotan II is not one of the six peptides the policy covers, per the policy appendix.
Caveat: Draft policy. The notice itself does not name the peptides; its appendix names six: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. We read the appendix through a text extraction, not the original PDF layout.
Verified Oct 31, 2026
- HHS draft policy pausing enforcement on six compounded peptides (Federal Register)
Status: Draft policy; comments open until Nov 14, 2026. Dihexa is not one of the six peptides the policy covers, per the policy appendix.
Caveat: Draft policy. The notice itself does not name the peptides; its appendix names six: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. We read the appendix through a text extraction, not the original PDF layout.
Verified Oct 31, 2026
- HHS draft policy pausing enforcement on six compounded peptides (Federal Register)
Status: Draft policy; comments open until Nov 14, 2026. GHK-Cu is not one of the six peptides the policy covers, per the policy appendix.
Caveat: Draft policy. The notice itself does not name the peptides; its appendix names six: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. We read the appendix through a text extraction, not the original PDF layout.
Verified Oct 31, 2026
- Investigational Peptides in Orthopaedic Practice: BPC-157, Thymosin Beta-4 and TB-500
Status: Online ahead of print. Narrative review (Tham, Hodgkins and Kennedy, J Am Acad Orthop Surg) searching through June 2026. Finds human musculoskeletal evidence limited to one small retrospective uncontrolled case series and no validated dosing, pharmacokinetic or long-term safety data. Concludes routine clinical use cannot currently be recommended.
Verified Oct 31, 2026
- Investigational Peptides in Orthopaedic Practice: BPC-157, Thymosin Beta-4 and TB-500
Status: Online ahead of print. Narrative review of BPC-157, thymosin beta-4 and TB-500, searched through June 2026. Calls TB-500 a distinct seven-amino-acid fragment often conflated with full-length thymosin beta-4. Finds no FDA-approved musculoskeletal indication, product quality concerns, and concludes routine clinical use cannot currently be recommended.
Caveat: Abstract read; full text not read.
Verified Oct 31, 2026
- Early Phase 1 topical anti-aging peptide serum study, one of five peptides (Frontiers in Bioscience Research Institute and Aging)
Status: Enrolling by invitation. Planned 48 participants, one site in Irvine, California. Estimated start Oct 21, 2026. No results posted.
Caveat: Epitalon is one of five peptides in a topical serum; not an injection study.
Verified Oct 31, 2026
- FDA label: Vyleesi (bremelanotide), supplement 5, revised 10/2026
Status: Approved. Indicated for premenopausal women with acquired, generalized HSDD; not for postmenopausal women, men or to enhance performance. Contraindicated in uncontrolled hypertension or known cardiovascular disease. Warnings: transient blood pressure rise, focal hyperpigmentation, nausea. 18% vs 2% discontinued for adverse reactions.
Caveat: Label PDF read. Compared with the 2020 label: marketer changed to Cosette and lactation data added; no other substantive change found by text comparison.
Verified Nov 2, 2026
- Early Phase 1 study with a topical serum of five peptides including GHK-Cu (Frontiers in Bioscience Research Institute in Aging and Cancer)
Status: Enrolling by invitation. Planned 48 participants, one site in Irvine, California. Estimated start Oct 21, 2026. No results posted.
Caveat: GHK-Cu is one of five peptides in a topical serum; not an injection study.
Verified Oct 31, 2026
- Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): phase 3 (Lancet)
Status: Published. Phase 3.
Caveat: Title and journal details only.
Verified Nov 1, 2026
- Epitalon and Epithalamin: A Narrative Review (Int J Mol Sci)
Status: Published. Human evidence limited to small studies; no adequately powered randomized trial.
Caveat: Review.
Verified Oct 31, 2026
- Narrative review of BPC-157 for liver protection (Sever et al., Pharmaceuticals)
Status: Published. Summarizes animal-model findings, including on portal hypertension. The authors state that experimental evidence, however extensive, does not establish clinical efficacy.
Caveat: Author list includes Predrag Sikiric and Sven Seiwerth, who also wrote several other recent BPC-157 papers in PubMed.
Verified Oct 31, 2026
- FDA page: concerns with unapproved GLP-1 drugs (990 adverse event reports for compounded semaglutide)
Status: Published. As of May 31, 2026 FDA had received 990 reports of adverse events associated with compounded semaglutide.
Caveat: Reports do not prove causation; underreporting is likely, per FDA.
Verified Nov 1, 2026
- FDA page: concerns with unapproved GLP-1 drugs used for weight loss (retatrutide and cagrilintide cannot be compounded)
Status: Cannot be compounded, per FDA. FDA says retatrutide and cagrilintide cannot be used in compounding under federal law and that it has warned telehealth firms and API distributors.
Caveat: Content current Oct 1, 2026 per the page.
Verified Nov 1, 2026
- FDA page: concerns with unapproved GLP-1 drugs used for weight loss (retatrutide and cagrilintide cannot be compounded)
Status: Cannot be compounded, per FDA. FDA says retatrutide and cagrilintide cannot be used in compounding under federal law.
Caveat: Content current Oct 1, 2026 per the page.
Verified Nov 1, 2026
- FDA page: concerns with unapproved GLP-1 drugs (730+ adverse event reports for compounded tirzepatide)
Status: Published. As of May 31, 2026 FDA had received more than 730 reports of adverse events associated with compounded tirzepatide.
Caveat: Reports do not prove causation.
Verified Nov 1, 2026
- BPC-157 pilot after rotator cuff repair (University of Arkansas)
Status: Not yet recruiting. Summary says 20 patients, enrollment field says 30.
Verified Oct 31, 2026
- FDA warning letter to NuScience Peptides LLC: tesamorelin-ipamorelin blend among unapproved new drugs
Status: Warning letter. Lists a Tesamorelin Ipamorelin Blend among products treated as unapproved new drugs.
Caveat: A statement about one firm's conduct.
Verified Nov 1, 2026
- FDA warning letter to Royal Peptides LLC: PT-141 among unapproved new drugs
Status: Warning letter. Lists PT-141, among others, as an unapproved new drug.
Caveat: A statement about one firm's conduct.
Verified Nov 2, 2026
- FDA warning letter to NuScience Peptides LLC: PT-141 Peptide (Bremelanotide) among unapproved new drugs
Status: Warning letter. Lists a PT-141 Peptide (Bremelanotide) product, among others, as an unapproved new drug.
Caveat: A statement about one firm's conduct.
Verified Nov 2, 2026
- FDA warning letter to Royal Peptides LLC: tesamorelin-ipamorelin blend among unapproved new drugs
Status: Warning letter. Cites a Tesamorelin and Ipamorelin blend sold as a research product.
Caveat: A statement about one firm's conduct.
Verified Nov 1, 2026
- FDA warning letter to Royal Peptides LLC: retatrutide among seven unapproved new drugs
Status: Warning letter. Lists retatrutide among seven products treated as unapproved new drugs despite "research use only" labeling.
Caveat: A statement about one firm's conduct.
Verified Nov 1, 2026
- FDA warning letter to NuScience Peptides LLC: tesamorelin products among unapproved new drugs
Status: Warning letter. Treats a Tesamorelin Research Peptide and a tesamorelin-ipamorelin blend, among others, as unapproved new drugs.
Caveat: A statement about one firm's conduct.
Verified Nov 1, 2026
- FDA warning letter to Royal Peptides LLC: tesamorelin among unapproved new drugs
Status: Warning letter. Treats Tesamorelin, among others, as an unapproved new drug.
Caveat: A statement about one firm's conduct.
Verified Nov 1, 2026
- A beverage with anti-fatigue and mood-regulating functions and its preparation method
Status: Published application, not granted. Applicant 南京医科大学. Filed Jul 15, 2026.
Caveat: Title as listed by Google Patents (machine translation). Legal status and claims not checked.
Verified Oct 31, 2026
- Polypeptide, polypeptide variant, preparation method, composition and application thereof
Status: Published application, not granted. Applicant 诺为泰(昆明)生物科技有限公司. Filed May 25, 2026.
Caveat: Title as listed by Google Patents (machine translation). Legal status and claims not checked; the link to BPC-157 is from the Google Patents text match.
Verified Oct 31, 2026
- Fifty 1 Labs Reg A offering (part II and III)
Status: Filed. Describes itself as a biotechnology company focused on peptide products, naming BPC-157 and TB-500.
Caveat: A company statement about its own business, not a finding about the peptide.
Verified Oct 31, 2026
- Fifty 1 Labs Reg A offering (part II and III)
Status: Filed. Biotechnology company focused on peptide products, naming BPC-157 and TB-500.
Verified Oct 31, 2026
- Open-label BPC-157 supplement gummy study (Parlay Wellness)
Status: Completed. 40 participants, 8 weeks, no control group, registered after it ended.
Verified Oct 31, 2026
- DailyMed: Egrifta WR (tesamorelin) label
Status: Approved. Same indication as Egrifta SV. Label revised 03/2025.
Caveat: Indication read; not the full label.
Verified Nov 1, 2026
- Holland & Knight: FDA advisory committee endorses compounding of certain peptides
Status: Published. Says the committee did not recommend emideltide and recommended the other six peptides it reviewed. Gives no vote counts.
Caveat: Law-firm summary, secondary source. Publication day not confirmed; August 2026.
Verified Oct 31, 2026
- DailyMed: Egrifta SV (tesamorelin) label
Status: Approved. Indicated for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. Label revised 03/2024.
Caveat: Indication, contraindications and warnings headings read; not the full label.
Verified Nov 1, 2026
- FDA Panel Backs 6 Peptides for Compounding (AJMC)
Status: Published. Reports an 8 yes, 6 no, 1 abstention vote covering BPC-157, KPV and TB-500 together; the committee recommended BPC-157.
Caveat: Press report of a nonbinding committee vote. FDA has posted no minutes or transcript, so the tally is unconfirmed.
Verified Nov 1, 2026
- FDA Panel Backs 6 Peptides for Compounding (AJMC)
Status: Published. Reports an 8 yes, 6 no, 1 abstention vote covering BPC-157, KPV and TB-500 together; the committee recommended KPV.
Caveat: Press report of a nonbinding committee vote. FDA has posted no minutes or transcript, so the tally is unconfirmed.
Verified Nov 1, 2026
- FDA Panel Backs 6 Peptides for Compounding (AJMC)
Status: Published. Reports an 8 yes, 6 no, 1 abstention vote covering BPC-157, KPV and TB-500 together; the committee recommended TB-500.
Caveat: Press report of a nonbinding committee vote. FDA has posted no minutes or transcript, so the tally is unconfirmed.
Verified Nov 1, 2026
- FDA Panel Backs 6 Peptides for Compounding (AJMC)
Status: Published. Reports a 7 yes, 5 no, 2 abstention vote; the committee recommended MOTS-c.
Caveat: Press report of a nonbinding committee vote. FDA has posted no minutes or transcript, so the tally is unconfirmed.
Verified Nov 1, 2026
- FDA Panel Backs 6 Peptides for Compounding (AJMC)
Status: Published. Reports the committee recommended Epitalon; gives no vote count for it.
Caveat: Press report of a nonbinding committee vote. FDA has posted no minutes or transcript, so the tally is unconfirmed.
Verified Nov 1, 2026
- FDA Panel Backs 6 Peptides for Compounding (AJMC)
Status: Published. Reports the committee recommended Semax; gives no vote count for it.
Caveat: Press report of a nonbinding committee vote. FDA has posted no minutes or transcript, so the tally is unconfirmed.
Verified Nov 1, 2026
- FDA Panel Backs 6 Peptides for Compounding (AJMC)
Status: Published. Reports a 6 yes, 7 no, 1 abstention vote; the committee did not recommend emideltide.
Caveat: Press report of a nonbinding committee vote. FDA has posted no minutes or transcript, so the tally is unconfirmed.
Verified Nov 1, 2026
- FDA advisory committee backs two more peptides, rejects one for compounding list (RAPS)
Status: Published. Reports a 6 yes, 7 no, 1 abstention vote; the committee did not recommend emideltide.
Caveat: Press report of a nonbinding committee vote. FDA has posted no minutes or transcript, so the tally is unconfirmed.
Verified Nov 1, 2026
- FDA Panel Votes to Loosen Restrictions for Four Peptides (Pharmaceutical Executive)
Status: Published. Reports a 7 yes, 5 no, 2 abstention vote; the committee recommended MOTS-c.
Caveat: Press report of a nonbinding committee vote. FDA has posted no minutes or transcript, so the tally is unconfirmed. The article describes a 14-member committee; its 8-6-1 tally adds to 15.
Verified Nov 1, 2026
- FDA Panel Votes to Loosen Restrictions for Four Peptides (Pharmaceutical Executive)
Status: Published. Reports an 8 yes, 6 no, 1 abstention vote covering BPC-157, KPV and TB-500 together; the committee recommended BPC-157.
Caveat: Press report of a nonbinding committee vote. FDA has posted no minutes or transcript, so the tally is unconfirmed. The article describes a 14-member committee; its 8-6-1 tally adds to 15.
Verified Nov 1, 2026
- FDA Panel Votes to Loosen Restrictions for Four Peptides (Pharmaceutical Executive)
Status: Published. Reports an 8 yes, 6 no, 1 abstention vote covering BPC-157, KPV and TB-500 together; the committee recommended TB-500.
Caveat: Press report of a nonbinding committee vote. FDA has posted no minutes or transcript, so the tally is unconfirmed. The article describes a 14-member committee; its 8-6-1 tally adds to 15.
Verified Nov 1, 2026
- FDA Panel Votes to Loosen Restrictions for Four Peptides (Pharmaceutical Executive)
Status: Published. Reports an 8 yes, 6 no, 1 abstention vote covering BPC-157, KPV and TB-500 together; the committee recommended KPV.
Caveat: Press report of a nonbinding committee vote. FDA has posted no minutes or transcript, so the tally is unconfirmed. The article describes a 14-member committee; its 8-6-1 tally adds to 15.
Verified Nov 1, 2026
- FDA advisory committee backs two more peptides, rejects one for compounding list (RAPS)
Status: Published. Reports an 8 yes, 5 no vote; the committee recommended Semax. Abstentions are not reported.
Caveat: Press report of a nonbinding committee vote. FDA has posted no minutes or transcript, so the tally is unconfirmed. This is the only source we found for this count.
Verified Nov 1, 2026
- STAT: FDA advisory panel narrowly rejects compounding of one peptide, backs two others
Status: Press report. Reports the panel voted 7-4 on epitalon on Jul 24, 2026. The article text we read does not label yes and no, and mentions no abstentions. RAPS reports 7-5-1; McDermott reports 7-4-1.
Caveat: Press report, not an official tally. Text read through a summarizing fetch, so the exact wording was not checked against the page.
Verified Nov 2, 2026
- STAT: FDA advisory panel narrowly rejects compounding of one peptide, backs two others
Status: Press report. Reports the vote on adding Semax for migraines was 8-5 on Jul 24, 2026. The article text we read does not label yes and no, and mentions no abstentions. RAPS also reports 8-5.
Caveat: Press report, not an official tally. Text read through a summarizing fetch, so the exact wording was not checked against the page.
Verified Nov 2, 2026
- FDA advisory committee backs two more peptides, rejects one for compounding list (RAPS)
Status: Published. Reports a 7 yes, 5 no, 1 abstention vote; the committee recommended epitalon.
Caveat: Press report of a nonbinding committee vote. FDA has posted no minutes or transcript, so the tally is unconfirmed. This is the only source we found for this count.
Verified Nov 1, 2026
- Effects of BPC-157 and TB-500 on Achilles tendon healing in rats
Status: Published. 32 rats after Achilles tendon repair, 4 weeks. TB-500 group had higher load to failure and better tendon scores than controls; the BPC-157 and TB-500 combination added no benefit over either alone. Authors call it exploratory.
Caveat: Abstract read; full text, funding and disclosures not read.
Verified Oct 31, 2026
- Public Citizen testimony to the Pharmacy Compounding Advisory Committee about BPC-157
Status: Testimony. Argues the benefit evidence is mostly anecdotal, no trials support the proposed routes, the mechanism is unclear, and impurities could raise immune risks.
Caveat: Advocacy group testimony, not a finding. Automated access was blocked in the latest check; the summary comes from the dossier earlier read.
Verified Oct 31, 2026
- Lilly press release: retatrutide TRIUMPH-2 and TRIUMPH-3 results; BLA planned Q1 2027
Status: Company press release. Reports average weight loss of 20.8% (TRIUMPH-2, 12 mg, 80 weeks) and up to 22.6% (TRIUMPH-3), and a planned BLA submission in Q1 2027.
Caveat: Company statement, read as reposted; not independently verified.
Verified Nov 1, 2026
- X39 patch and circulating GHK and GHK-Cu levels in healthy adults (LifeWave)
Status: Not yet recruiting. Tests a patch, not GHK-Cu itself. Planned 100 participants, one site in London, Canada. Estimated start Jan 2027.
Caveat: Registry entry is sponsor-written.
Verified Oct 31, 2026
- Sublingual semaglutide-BPC 157 combination for weight loss
Status: Published application, not granted. Applicant Red Mountain Med Spa, LLC. Priority May 15, 2023, filed Feb 20, 2026.
Caveat: Legal status not checked. Claims not read.
Verified Oct 31, 2026
- Systematic review of GHK-Cu in topical microneedle delivery (Arch Intern Med Res)
Status: Published. Says the human literature is thin and fragmented, with most randomized trials small and on facial cosmetic creams.
Caveat: Review; abstract only; journal not assessed. PubMed gives no day, so the date shown is approximate.
Verified Oct 31, 2026
- Spinnaker ETF Series 485APOS
Status: Filed. Risk language noting the July 23-24 FDA committee meeting would evaluate BPC-157 among other peptides.
Caveat: A company statement about its own business, not a finding about the peptide.
Verified Oct 31, 2026
- Application of gastric pentadecapeptide in the preparation of drugs for treating immune checkpoint inhibitor-associated colitis
Status: Published application, not granted. Applicant 陕西医药控股医药研究院有限公司. Filed Apr 30, 2026.
Caveat: Title as listed by Google Patents (machine translation). Legal status and claims not checked.
Verified Oct 31, 2026
- Apparatus and method for peptide stack determination
Status: Published. Applicant: Ageless Medicine Systems. Priority Dec 10, 2024.
Caveat: Claims and legal status not read.
Verified Oct 31, 2026
- Preprint: GHK-Cu in middle-aged mice, intraperitoneal or intranasal (Res Sq)
Status: Published. Mouse study.
Caveat: Preprint, not peer reviewed; abstract only.
Verified Oct 31, 2026
- BPC-157 sodium salt oral dissolving film formulation for treating acute alcohol poisoning and its preparation method
Status: Published application, not granted. Applicant 杭州昊肽生物科技有限公司. Filed Feb 6, 2026.
Caveat: Title as listed by Google Patents (machine translation). Legal status and claims not checked.
Verified Oct 31, 2026
- DailyMed: Pitocin (oxytocin) label
Status: Approved. Not indicated for elective induction of labor; IV use under hospital supervision for induction or augmentation. Also indicated postpartum for contractions and bleeding. Lists uterine rupture, postpartum hemorrhage, fatal afibrinogenemia and water intoxication among reactions.
Caveat: Full label text read.
Verified Nov 2, 2026
- FDA briefing document for July 2026 advisory committee: TB-500 (free base and acetate)
Status: Proposed not to add to 503A list. No human data found. No repeat-dose, genotoxicity or carcinogenicity studies. Poorly characterized. Immunogenicity risk.
Verified Oct 31, 2026
- FDA briefing document for July 2026 advisory committee: KPV (free base and acetate)
Status: Proposed not to add to 503A list. No human data. 8 nonclinical articles submitted. Not well characterized. No FAERS reports.
Verified Oct 31, 2026
- FDA briefing document for July 2026 advisory committee: Epitalon (free base and acetate)
Status: Proposed not to add to 503A list. No clinical safety data in humans. Effectiveness for insomnia not shown. Telomerase and cancer-risk concern. No FAERS reports.
Verified Oct 31, 2026
- BioScience Health Innovations 10-Q listing "PEG-MGF - Muscle repair"
Status: Filed. Lists PEG-MGF among 14 peptides the company expects to return to Category 1, citing a Feb 27, 2026 statement by the HHS Secretary. Says reclassification is not FDA approval.
Caveat: Company claim, not a finding. Read the passages naming the peptide only.
Verified Oct 31, 2026
- BioScience Health Innovations 10-Q
Status: Filed. Filed May 11, 2026, listed alongside the 10-K on the dossier. Its contents were not summarized separately.
Caveat: Contents not separately read. A company statement about its own business, not a finding about the peptide.
Verified Oct 31, 2026
- FDA staff briefing for the committee on BPC-157
Status: Criteria weighed against listing. Only UC use evaluated; sparse human data; animal clotting and liver signals.
Verified Oct 31, 2026
- FDA briefing document for July 2026 advisory committee: MOTS-c (free base and acetate)
Status: Proposed not to add to 503A list. No clinical or human exposure data. Cell and rodent models only. Not well characterized. No FAERS reports.
Verified Oct 31, 2026
- FDA briefing document for July 2026 advisory committee: Emideltide (free base and acetate)
Status: Proposed not to add to 503A list. Balance of criteria weighs against listing. Not well characterized; effectiveness evidence insufficient; no clinical safety data for the proposed subcutaneous route. No FAERS reports through Mar 3, 2024.
Verified Oct 31, 2026
- BioScience Health Innovations 10-Q listing "Melanotan II - Skin pigmentation"
Status: Filed. Lists Melanotan II among 14 peptides the company expects to return to Category 1, citing a Feb 27, 2026 statement by the HHS Secretary. Says reclassification is not FDA approval.
Caveat: Company claim, not a finding. Read the passages naming the peptide only.
Verified Oct 31, 2026
- FDA briefing document for July 2026 advisory committee: Semax (free base and acetate)
Status: Proposed not to add to 503A list. No human pharmacokinetic data. Effectiveness evidence insufficient. One FAERS consumer report (eye pain after nasal drops).
Verified Oct 31, 2026
- BioScience Health Innovations 10-Q listing "DSIP (Emideltide)"
Status: Filed. Lists emideltide among 14 peptides the company expects to return to Category 1, citing a Feb 27, 2026 statement by the HHS Secretary. Says reclassification is not FDA approval.
Caveat: Company claim, not a finding. Read the passages naming the peptide only.
Verified Oct 31, 2026
- BioScience Health Innovations 10-Q listing GHK-Cu
Status: Filed. Lists GHK-Cu among 14 peptides the company expects to return to Category 1, citing a Feb 27, 2026 statement by the HHS Secretary. Says reclassification is not FDA approval.
Caveat: Company claim, not a finding. Read the passages naming the peptide only.
Verified Oct 31, 2026
- FDA page: bulk substances that may present significant safety risks (PEG-MGF)
Status: Listed (nominated but withdrawn)
Caveat: Content current Apr 22, 2026 per the page.
Verified Oct 31, 2026
- FDA page: bulk substances that may present significant safety risks (ipamorelin)
Status: Listed. Category 2 under the 503B interim policy (added Sep 29, 2023) and also listed as nominated but withdrawn. Immunogenicity risk; unnatural amino acids; a published study reported serious adverse events including death with intravenous use for gastric motility.
Caveat: Content current Apr 22, 2026. Read in full.
Verified Nov 1, 2026
- FDA page: bulk substances that may present significant safety risks (selank acetate (TP-7))
Status: Listed. Nominated but withdrawn. Immunogenicity risk for certain routes; lacks important safety information in humans.
Caveat: Content current Apr 22, 2026. Read in full.
Verified Nov 1, 2026
- FDA page: bulk substances that may present significant safety risks (Epitalon)
Status: Listed (nominated but withdrawn). Listed under substances nominated but withdrawn. FDA has not identified safety-related information for the proposed route. Content current Apr 22, 2026.
Verified Oct 31, 2026
- FDA page: bulk substances that may present significant safety risks (GHRP-2)
Status: Listed. Category 2 under the 503B interim policy for injectable and nasal routes (added Sep 29, 2023). Reports of serious adverse events including death of critically ill study subjects; causality not established.
Caveat: Content current Apr 22, 2026. Read in full.
Verified Nov 1, 2026
- FDA page: bulk substances that may present significant safety risks (Semax)
Status: Listed. Immunogenicity risk for certain routes; no, or limited, safety information for proposed routes. Content current Apr 22, 2026.
Verified Oct 31, 2026
- FDA page: bulk substances that may present significant safety risks (LL-37)
Status: Listed (nominated but withdrawn)
Caveat: Content current Apr 22, 2026 per the page.
Verified Oct 31, 2026
- FDA page: bulk substances that may present significant safety risks (MOTS-c)
Status: Listed. Immunogenicity risk for certain routes; peptide-related impurity and characterization concerns. No human exposure data identified. Content current Apr 22, 2026.
Verified Oct 31, 2026
- FDA page: bulk substances that may present significant safety risks (AOD-9604)
Status: Listed. Nominated but withdrawn. Significant immunogenicity risk; no or limited safety information; serious adverse events that may be associated with it, causality not clear.
Caveat: Content current Apr 22, 2026. Read in full.
Verified Nov 1, 2026
- FDA page: bulk substances that may present significant safety risks (KPV)
Status: Listed. No human exposure data identified by FDA for any route. Content current Apr 22, 2026.
Verified Oct 31, 2026
- FDA page: bulk substances that may present significant safety risks (CJC-1295)
Status: Listed (nominated but withdrawn). Immunogenicity risk for certain routes; peptide-related impurity and characterization complexities; serious adverse events including increased heart rate and systemic vasodilatory reaction; limited clinical data.
Caveat: Content current Apr 22, 2026 per the page.
Verified Nov 1, 2026
- FDA page: bulk substances that may present significant safety risks (GHK-Cu)
Status: Listed (nominated but withdrawn)
Caveat: Content current Apr 22, 2026 per the page.
Verified Oct 31, 2026
- FDA page: bulk substances that may present significant safety risks (thymosin-alpha 1)
Status: Listed. Nominated but withdrawn. Significant immunogenicity risk; safety-related information inadequate to understand the extent of safety issues.
Caveat: Content current Apr 22, 2026. Read in full.
Verified Nov 1, 2026
- FDA page: bulk substances that may present significant safety risks (GHRP-6)
Status: Listed. Category 2 under the 503B interim policy (added Sep 29, 2023). Immunogenicity risk; limited safety data show a potential effect on cortisol and increased blood glucose from decreased insulin sensitivity.
Caveat: Content current Apr 22, 2026. Read in full.
Verified Nov 1, 2026
- FDA page: bulk substances that may present significant safety risks (ibutamoren mesylate)
Status: Listed. Category 2 under both 503A (added Sep 29, 2023) and 503B (added Dec 29, 2022). Significant safety risks due to potential congestive heart failure; cites a hip-fracture trial terminated early for a possible heart failure signal.
Caveat: Content current Apr 22, 2026. Read in full.
Verified Nov 1, 2026
- FDA page: bulk substances that may present significant safety risks (kisspeptin-10)
Status: Listed. Category 2 under the 503A interim policy (added Sep 29, 2023). FDA has no, or only limited, safety information for the proposed routes and lacks sufficient information to know whether the drug would cause harm.
Caveat: Content current Apr 22, 2026. Read in full.
Verified Nov 1, 2026
- FDA page: bulk substances that may present significant safety risks (Dihexa)
Status: Listed (nominated but withdrawn)
Caveat: Content current Apr 22, 2026 per the page.
Verified Oct 31, 2026
- FDA page: bulk substances that may present significant safety risks (BPC-157)
Status: Listed. Says compounded drugs containing BPC-157 may pose immunogenicity risk for certain routes and have peptide-impurity and ingredient-characterization problems. FDA found no or only limited safety information for the proposed routes. Content current Apr 22, 2026.
Verified Oct 31, 2026
- FDA page: bulk substances that may present significant safety risks (thymosin beta-4 fragment LKKTETQ, TB-500)
Status: Listed. Immunogenicity risk for certain routes; no human exposure data identified. Content current Apr 22, 2026.
Verified Oct 31, 2026
- FDA page: bulk substances that may present significant safety risks (Melanotan II)
Status: Listed (nominated but withdrawn)
Caveat: Content current Apr 22, 2026 per the page.
Verified Oct 31, 2026
- FDA page: bulk substances that may present significant safety risks (Emideltide)
Status: Listed (nominated but withdrawn). FDA has not identified safety-related information for the proposed route of administration.
Caveat: Content current Apr 22, 2026 per the page.
Verified Oct 31, 2026
- FDA notice of July 2026 advisory committee meeting on seven peptides
Status: Published. GHK-Cu is not among the substances the notice lists.
Caveat: Read directly.
Verified Oct 31, 2026
- FDA notice of July 2026 advisory committee meeting on seven peptides
Status: Published. LL-37 is not among the substances the notice lists.
Caveat: Read directly.
Verified Oct 31, 2026
- FDA notice of July 2026 advisory committee meeting on seven peptides
Status: Published. Melanotan II is not among the substances the notice lists.
Caveat: Read directly.
Verified Oct 31, 2026
- FDA notice of July 2026 advisory committee meeting naming emideltide
Status: Published. Lists emideltide with opioid withdrawal, chronic insomnia and narcolepsy as evaluated uses.
Caveat: Read directly.
Verified Oct 31, 2026
- FDA notice of July 2026 advisory committee meeting on seven peptides
Status: Published. Dihexa is not among the substances the notice lists.
Caveat: Read directly.
Verified Oct 31, 2026
- FDA notice of July 2026 advisory committee meeting on seven peptides
Status: Published. PEG-MGF is not among the substances the notice lists.
Caveat: Read directly.
Verified Oct 31, 2026
- Simultaneous analysis of food-borne doping substances using liquid ... (a testing method; title shortened)
Status: Published application. Applicant: Korea Institute of Science and Technology. Priority Oct 7, 2024.
Caveat: Claims and legal status not read.
Verified Oct 31, 2026
- Phase 2a placebo-controlled MOTS-c study in prediabetes with overweight/obesity (Hudson Biotech)
Status: Recruiting. Planned 120 participants, 12 weeks subcutaneous MOTS-c vs placebo, one site in Shenzhen. Estimated primary completion Feb 2027. No results posted.
Caveat: Same sponsor as a TB-500 record whose summary calls itself fictional; this record does not contain that wording. Unverified.
Verified Oct 31, 2026
- BioScience Health Innovations 10-K
Status: Filed. Says its oral delivery system could unlock commercial pathways for formulations containing BPC-157 if FDA formally enacts a reclassification of peptides that the company describes as announced Feb 27, 2026. Lists BPC-157 among peptides it aims to deliver orally.
Caveat: A company statement about its own business, not a finding about the peptide.
Verified Oct 31, 2026
- Phase 1/2 placebo-controlled TB-500 study in stable ASCVD (Hudson Biotech)
Status: Recruiting. Planned 80 participants, three dose cohorts, one site in Shenzhen. Estimated primary completion Feb 2027. No results posted.
Caveat: Record summary says: This fictional study is an example of a ClinicalTrials.gov-style record. Unverified.
Verified Oct 31, 2026
- A Paradise Acquisition Corp. Rule 425 (merger partner Enhanced Ltd.)
Status: Filed. A shareholder email from its merger partner, Enhanced Ltd., lists BPC-157 among peptides it intends to provide if the regulatory change occurs.
Caveat: A company statement about its own business, not a finding about the peptide.
Verified Oct 31, 2026
- A Paradise Acquisition Corp. Rule 425 (merger partner Enhanced Ltd.) naming GHK-Cu
Status: Filed. A shareholder email lists GHK-Cu among "already allowed peptides" the partner plans to launch.
Caveat: Company claim, not a finding. What "already allowed" refers to is not stated.
Verified Oct 31, 2026
- Phase 2 Melanotan II adjunct to NB-UVB phototherapy in vitiligo (Hudson Biotech)
Status: Recruiting. Planned 60 participants, one site, Peking University Shenzhen Hospital. Started Feb 2, 2026. Dose and route given only as "per protocol". No results posted.
Caveat: Summary begins "This example interventional study record describes". Same sponsor, site and start date as the BPC-157, TB-500, MOTS-c and GHK-Cu records. Cannot be independently confirmed.
Verified Oct 31, 2026
- Phase 2 placebo-controlled BPC-157 in acute hamstring strain (Hudson Biotech)
Status: Recruiting. Planned 120 participants, Shenzhen, started Feb 2, 2026.
Verified Oct 31, 2026
- Phase 2 topical GHK-Cu gel for acute skin wound healing (Hudson Biotech)
Status: Recruiting. Planned 60 participants, one site, Peking University Shenzhen Hospital. Started Feb 2, 2026. No results posted.
Caveat: Same sponsor, site and start date as the BPC-157, TB-500, MOTS-c and Melanotan II records; the TB-500 record calls itself a fictional example. Cannot be independently confirmed.
Verified Oct 31, 2026
- Synergistic combination of NAD+ and therapeutic peptides delivered via ... (title shortened by Google Patents)
Status: Published application. Applicant: Nicholas Jerome Andrews. Priority Apr 22, 2024. Second US application in the same family of titles.
Caveat: Claims and legal status not read.
Verified Oct 31, 2026
- Systemic MOTS-c levels are increased in adults with obesity (J Clin Transl Endocrinol)
Status: Published. 32 obese vs 22 lean adults; 10 followed after bariatric surgery. Measured levels only.
Verified Oct 31, 2026
- WADA 2022 and 2026 Prohibited Lists: mechano growth factors (MGFs) named; PEG-MGF not named
Status: MGFs named as a class
Caveat: Only the 2022 and 2026 editions were checked. We found no WADA text naming PEG-MGF or addressing pegylated forms.
Verified Oct 31, 2026
- WADA 2022 and 2026 Prohibited Lists: Epitalon not named
Status: Not named
Caveat: Only the 2022 and 2026 editions were checked. Section S0 covers substances with no government approval.
Verified Oct 31, 2026
- WADA 2026 Prohibited List: selank not found
Status: Not named
Caveat: Searched WADA's own 2026 file through a text extraction and a copy hosted by an athletics federation. Only the 2026 edition was checked.
Verified Nov 1, 2026
- WADA 2026 Prohibited List, S2.2.4: ipamorelin named among growth hormone secretagogues
Status: Prohibited
Caveat: Read from WADA's own file through a text extraction and cross-checked against a copy hosted by an athletics federation. 2026 edition only.
Verified Nov 1, 2026
- WADA 2022 and 2026 Prohibited Lists: Melanotan II not named
Status: Not named
Caveat: Only the 2022 and 2026 editions were checked. Section S0 covers substances with no government approval.
Verified Oct 31, 2026
- Review of performance-enhancing peptides modulating the GH-IGF1 axis (Front Endocrinol (Lausanne))
Status: Published. Lists PEG-MGF among IGF-1 analogues marketed as research compounds; adverse effects reported for the group.
Caveat: Review; effects not specific to PEG-MGF; abstract only. PubMed gives no day or month, so the date shown is approximate.
Verified Oct 31, 2026
- WADA 2026 Prohibited List: pinealon not found
Status: Not named
Caveat: Searched WADA's own 2026 file through a text extraction and a copy hosted by an athletics federation. Only the 2026 edition was checked.
Verified Nov 2, 2026
- WADA 2026 Prohibited List: thymalin not found
Status: Not named
Caveat: Searched WADA's own 2026 file through a text extraction and a copy hosted by an athletics federation. Only the 2026 edition was checked.
Verified Nov 2, 2026
- MPTP-associated pancreatic injury and its attenuation by hexarelin in mice (J Mol Histol)
Status: Published. Mouse study.
Caveat: Title read; animal study.
Verified Nov 2, 2026
- WADA 2022 and 2026 Prohibited Lists: Dihexa not named
Status: Not named
Caveat: Only the 2022 and 2026 editions were checked. The 2026 list names hepatocyte growth factor in S2.3; whether S2.3 reaches dihexa is not stated by WADA in anything we read.
Verified Oct 31, 2026
- WADA 2026 Prohibited List, S2.2.4: examorelin (hexarelin) named among GH-releasing peptides
Status: Prohibited
Caveat: Read from WADA's own file through a text extraction and cross-checked against a copy hosted by an athletics federation. 2026 edition only.
Verified Nov 2, 2026
- WADA 2022 and 2026 Prohibited Lists: GHK-Cu not named
Status: Not named
Caveat: Only the 2022 and 2026 editions were checked. Section S0 covers substances with no government approval.
Verified Oct 31, 2026
- WADA 2026 Prohibited List: retatrutide not named
Status: Not named
Caveat: Read from a copy of the 2026 list; WADA's own file would not open. Only the 2026 edition was checked. Section S0 covers substances with no government approval.
Verified Nov 1, 2026
- WADA 2026 Prohibited List, S2.4: CJC-1295 named among growth hormone releasing factors
Status: Prohibited
Caveat: Read from a copy of the list hosted by an athletics federation; WADA's own file would not open. 2026 edition only.
Verified Nov 1, 2026
- WADA 2026 Prohibited List: bremelanotide / PT-141 not found
Status: Not named
Caveat: Searched WADA's own 2026 file through a text extraction and a copy hosted by an athletics federation. Only the 2026 edition was checked.
Verified Nov 2, 2026
- WADA 2026 Prohibited List, S2.2.4: tesamorelin named among GHRH analogues
Status: Prohibited
Caveat: Read from WADA's own file through a text extraction and cross-checked against a copy hosted by an athletics federation. 2026 edition only.
Verified Nov 1, 2026
- WADA 2022 and 2026 Prohibited Lists: LL-37 not named
Status: Not named
Caveat: Only the 2022 and 2026 editions were checked. Section S0 covers substances with no government approval.
Verified Oct 31, 2026
- WADA 2026 Prohibited List, S2.2.4: sermorelin named among GHRH analogues
Status: Prohibited
Caveat: Read from WADA's own file through a text extraction and cross-checked against a copy hosted by an athletics federation. 2026 edition only.
Verified Nov 1, 2026
- WADA 2026 Prohibited List: cagrilintide not named
Status: Not named
Caveat: Read from a copy of the 2026 list; WADA's own file would not open. Only the 2026 edition was checked. Section S0 covers substances with no government approval.
Verified Nov 1, 2026
- WADA 2026 Prohibited List, S2.2.1: kisspeptin and its agonist analogues named among testosterone-stimulating peptides in males
Status: Prohibited
Caveat: Read from WADA's own file through a text extraction and cross-checked against a copy hosted by an athletics federation. 2026 edition only.
Verified Nov 1, 2026
- Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men (Eur J Endocrinol)
Status: Published. 15 men in three small studies; LH rise sustained with 8-hour daily infusions.
Caveat: Abstract read.
Verified Nov 1, 2026
- WADA 2026 Prohibited List, S2.2.4: ibutamoren (MK-677) named among GH secretagogues
Status: Prohibited
Caveat: Read from WADA's own file through a text extraction and cross-checked against a copy hosted by an athletics federation. 2026 edition only.
Verified Nov 1, 2026
- WADA 2026 Prohibited List: semaglutide not named
Status: Not named
Caveat: Read from a copy of the 2026 list; WADA's own file would not open. Only the 2026 edition was checked. Section S0 covers substances with no government approval.
Verified Nov 1, 2026
- WADA 2026 Prohibited List, S2.2.4: GHRP-6 named among GH-releasing peptides
Status: Prohibited
Caveat: Read from WADA's own file through a text extraction and cross-checked against a copy hosted by an athletics federation. 2026 edition only.
Verified Nov 1, 2026
- WADA 2026 Prohibited List: thymosin alpha-1 not found
Status: Not named
Caveat: Searched WADA's own 2026 file through a text extraction and a copy hosted by an athletics federation. Only the 2026 edition was checked.
Verified Nov 1, 2026
- WADA 2026 Prohibited List: tirzepatide not named
Status: Not named
Caveat: Read from a copy of the 2026 list; WADA's own file would not open. Only the 2026 edition was checked. Section S0 covers substances with no government approval.
Verified Nov 1, 2026
- WADA 2026 Prohibited List, S2.2.3: AOD-9604 named among growth hormone fragments
Status: Prohibited
Caveat: Read from WADA's own file through a text extraction and cross-checked against a copy hosted by an athletics federation. 2026 edition only.
Verified Nov 1, 2026
- WADA 2022 and 2026 Prohibited Lists: KPV not named
Status: Not named
Caveat: Only the 2022 and 2026 editions were checked. Section S0 covers substances with no government approval.
Verified Oct 31, 2026
- WADA 2026 Prohibited List, S4.4.1: mitochondrial open reading frame of the 12S rRNA-c (MOTS-c)
Status: Prohibited
Caveat: 2022 and 2026 editions checked; 2022 does not name it.
Verified Oct 31, 2026
- WADA 2022 and 2026 Prohibited Lists: emideltide and DSIP not named
Status: Not named
Caveat: Only the 2022 and 2026 editions were checked. Section S0 covers substances with no government approval.
Verified Oct 31, 2026
- WADA 2026 Prohibited List: oxytocin not found
Status: Not named
Caveat: Searched WADA's own 2026 file through a text extraction and a copy hosted by an athletics federation. Only the 2026 edition was checked.
Verified Nov 2, 2026
- WADA 2026 Prohibited List, S2.2.4: GHRP-2 (pralmorelin) named among GH-releasing peptides
Status: Prohibited
Caveat: Read from WADA's own file through a text extraction and cross-checked against a copy hosted by an athletics federation. 2026 edition only.
Verified Nov 1, 2026
- WADA 2022 and 2026 Prohibited Lists: Semax not named
Status: Not named
Caveat: Only the 2022 and 2026 editions were checked. Section S0 covers substances with no government approval.
Verified Oct 31, 2026
- Novo Nordisk release: NDA filed with FDA for CagriSema
Status: Company press release. Says Novo Nordisk filed an NDA for CagriSema, reports REDEFINE 1 weight loss of 20.4% versus 3.0% on placebo at 68 weeks, and says FDA is expected to review it in 2026.
Caveat: Company statement, read as reposted. No FDA decision found as of Nov 1, 2026.
Verified Nov 1, 2026
- Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes (N Engl J Med)
Status: Published. Phase 3.
Verified Nov 1, 2026
- Carnyx Therapeutics Form C offering statement naming epitalon
Status: Filed. Company says its sleep program is a peptide analog of epitalon, and that epitalon is off-patent.
Caveat: Company claim, not a finding. Filing day not shown in the document; December 2025.
Verified Oct 31, 2026
- Synergistic combination of NAD+ and therapeutic peptides delivered via ... (title shortened by Google Patents)
Status: Published application. Applicant: Nicholas Jerome Andrews. Priority Apr 22, 2024. Matched TB-500 with thymosin.
Caveat: Claims and legal status not read.
Verified Oct 31, 2026
- Regenerative Medical Technology Group 10-Q (BPC-157 and TB-500 pen)
Status: Filed. Describes a preloaded BPC-157 and TB-500 injectable pen as its current best seller.
Caveat: A company statement about its own business, not a finding about the peptide.
Verified Oct 31, 2026
- FDA warning letter to SimpleRx: semaglutide claims
Status: Warning letter. Says website claims such as "Semaglutide (Ozempic)" imply compounded products are the same as an FDA-approved product, and are false or misleading.
Caveat: A statement about one firm's conduct.
Verified Nov 1, 2026
- FDA warning letter to GLP-1 Solution: compounded retatrutide
Status: Warning letter. Says the firm's compounded retatrutide products are unapproved new drugs and misbranded and fail the conditions of sections 503A and 503B.
Caveat: A statement about one firm's conduct.
Verified Nov 1, 2026
- FDA warning letter to SemaBio: "generic semaglutide" claims
Status: Warning letter. Says website claims such as "generic semaglutide" are false or misleading because compounded drugs are not FDA-approved.
Caveat: A statement about one firm's conduct.
Verified Nov 1, 2026
- Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma? (Int J Oral Maxillofac Surg)
Status: Published. Case report posing the question.
Caveat: Case report; title only. PubMed gives no day, so the date shown is approximate.
Verified Oct 31, 2026
- Regenerative Medical Technology Group 10-Q (BPC-157 and TB-500 pen)
Status: Filed. Describes a BPC-157 and TB-500 injectable pen as current best seller.
Verified Oct 31, 2026
- Regenerative Medical Technology Group 10-Q (BPC-157 and TB-500 pen)
Status: Filed. Describes a preloaded BPC-157 and TB-500 injectable pen as its current best seller.
Caveat: A company statement about its own business, not a finding about the peptide.
Verified Oct 31, 2026
- Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1; N Engl J Med)
Status: Published. Phase 3.
Verified Nov 1, 2026
- Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes (REDEFINE 2; N Engl J Med)
Status: Published. Phase 3.
Verified Nov 1, 2026
- Systematic review of BPC-157 in orthopaedic sports medicine (Vasireddi et al., HSS Journal)
Status: Published. Of 36 articles, 35 were preclinical and 1 was clinical. Authors conclude it shows promise in animal models, that human safety is unknown, and urge caution. Animal safety data covered six weeks or less.
Verified Oct 31, 2026
- Russian State Register of Medicines: Selank nasal drops, Peptogen, registered 15.07.2025
Status: Registered. Register results table lists Selank nasal drops (капли назальные), holder AO INPC Peptogen, Russia, registration number ЛП-№(010951)-(РГ-RU), registration date 15.07.2025.
Caveat: Search page link only: the register has no direct link to a record. Search the trade name Селанк. We read the results table, not the full registration card.
Verified Nov 1, 2026
- Russian drug-reference page (RLS): Selank 0.15% nasal drops, registration ЛП-010951, holder Peptogen
Status: Listed as registered. Indications listed: anxiety states and prevention and treatment of stress disorders. Last revision 15.07.2025.
Caveat: A commercial drug reference, not the state register. No registration date or current-validity statement on the page.
Verified Nov 1, 2026
- Tirzepatide as compared with semaglutide for the treatment of obesity (N Engl J Med)
Status: Published. Phase 3.
Verified Nov 1, 2026
- Composition for tissue regeneration and wound healing containing thymosin beta- ... (title shortened by Google Patents)
Status: Published application. Applicant: Korea Institute of Science and Technology. Priority Dec 19, 2023.
Caveat: Claims and legal status not read.
Verified Oct 31, 2026
- Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis (N Engl J Med)
Status: Published. Phase 3.
Verified Nov 1, 2026
- openFDA enforcement data: four recalls of compounded CJC-1295 products
Status: Class II recalls. All four for lack of assurance of sterility; firms are compounding pharmacies.
Caveat: A sterility recall concerns how a product was made, not the substance. Some products were blends.
Verified Nov 1, 2026
- Retraction notice for the 2014 dihexa mechanism paper (J Pharmacol Exp Ther)
Status: Published. Notice of retraction of PMID 25187433.
Caveat: PubMed record shows no stated reason; notice not read. PubMed gives no day, so the date shown is approximate.
Verified Oct 31, 2026
- FDA page on the end of the GLP-1 shortage and compounding discretion (semaglutide)
Status: Shortage resolved. FDA determined the semaglutide injection shortage resolved Feb 21, 2025; stated discretion ended Apr 22, 2025 (503A) and May 22, 2025 (503B).
Caveat: Content current Apr 1, 2026 per the page.
Verified Nov 1, 2026
- Arginine-vasopressin dynamics and 8-week intranasal oxytocin treatment in adults with obesity (J Clin Endocrinol Metab)
Status: Published. 61 randomized to 24 IU four times daily or placebo; vasopressin did not change significantly with oxytocin versus placebo.
Caveat: Abstract read.
Verified Nov 2, 2026
- FDA page on the end of the GLP-1 shortage and compounding discretion (tirzepatide)
Status: Shortage resolved. FDA first resolved the shortage Oct 2, 2024; after a court remand it issued a new decision Dec 19, 2024. Stated discretion ended Feb 18, 2025 (503A) and Mar 19, 2025 (503B).
Caveat: Content current Apr 1, 2026 per the page.
Verified Nov 1, 2026
- FDA briefing document for Dec 4, 2024 advisory committee: CJC-1295 and related substances
Status: Proposed not to add to 503A list. Five CJC-1295-related substances evaluated. FDA cites unclear characterization and naming, safety concerns in nonclinical studies, and no clinical effectiveness data for growth hormone deficiency. Human studies only in healthy adults (63 exposed).
Caveat: Describes a 2006 phase 2 trial terminated after a participant died; says the data were never published.
Verified Nov 1, 2026
- Application of TB500 in the preparation of drugs for preventing or treating ... (title shortened by Google Patents)
Status: Published application. Applicant: Guangdong Ocean University. Priority Aug 30, 2023.
Caveat: Claims and legal status not read.
Verified Oct 31, 2026
- Tirzepatide for the treatment of obstructive sleep apnea and obesity (N Engl J Med)
Status: Published. Phase 3.
Verified Nov 1, 2026
- Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW; N Engl J Med)
Status: Published. Phase 3.
Verified Nov 1, 2026
- Quantification of TB-500 and its metabolites in vitro and in rats (UHPLC-Orbitrap MS/MS)
Status: Published. Analytical method paper with in-vitro wound-healing screening.
Caveat: Abstract read. Full text, funding and disclosures not read. Dated from PubMed (issue date Mar 1, 2024, online Feb 7, 2024).
Verified Oct 31, 2026
- Athira Pharma Form 10-K (fiscal 2023): special committee findings and the dihexa patent
Status: Filed. Company says its special committee found altered images in a former executive's dissertation and at least four papers published 2011-2014, and that the licensed dihexa patent incorporated some.
Caveat: Company statement, not a finding by an authority. Individuals not named here. Passages only.
Verified Oct 31, 2026
- Oxytocin in neurodevelopmental disorders: autism spectrum disorder and Prader-Willi syndrome (Pharmacol Ther)
Status: Published. Review; clinical trials show discrepant results.
Caveat: Abstract read.
Verified Nov 2, 2026
- Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors (AIDS)
Status: Published. Secondary analysis of a 61-person trial.
Caveat: Abstract read.
Verified Nov 1, 2026
- Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT; N Engl J Med)
Status: Published. Phase 3.
Verified Nov 1, 2026
- FDA approval record: Zepbound (NDA 217806)
Status: Approved. Original approval Nov 8, 2023 per Drugs@FDA.
Verified Nov 1, 2026
- Randomized trial of LL-37 cream in diabetic foot ulcers (Arch Dermatol Res)
Status: Published. Greater increase in granulation index with LL-37 on days 7 to 28.
Caveat: Abstract only. PubMed gives no day, so the date shown is approximate.
Verified Oct 31, 2026
- Co-administered once-weekly cagrilintide 2.4 mg with semaglutide 2.4 mg (Lancet)
Status: Published. Phase 1b.
Caveat: Title and journal details only.
Verified Nov 1, 2026
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: phase 2 (Lancet)
Status: Published. Phase 2.
Verified Nov 1, 2026
- Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial (N Engl J Med)
Status: Published. Phase 2.
Verified Nov 1, 2026
- Randomized trial of recombinant Lactococcus lactis "Oral LL-37" in COVID-19, 238 inpatients (J Med Virol)
Status: Published. Authors report shorter time to negative viral test with early treatment and no severe adverse events.
Caveat: Product is a recombinant bacterium preparation, not the peptide. Abstract only. PubMed gives no day, so the date shown is approximate.
Verified Oct 31, 2026
- Warning letter to Warrior Labz naming TB-500 and BPC-157
Status: Issued. Online seller offering TB-500 and BPC-157 alongside SARMs.
Caveat: Found by web search; list may be incomplete.
Verified Oct 31, 2026
- Warning letter to Warrior Labz (online seller)
Status: Issued. Its website took orders for BPC-157 (injectable and nasal spray) and TB-500, alongside SARMs and other products. Issued by FDA drug center.
Caveat: Found by web search and opened; list of letters may be incomplete. A letter states FDA position at the time, not a court finding.
Verified Oct 31, 2026
- Anterior pituitary reserve assessed by the GHRP-2 test in the elderly (Growth Horm IGF Res)
Status: Published. Diagnostic test study.
Caveat: Title only.
Verified Nov 1, 2026
- Thymalin dipeptide mechanism study (Int J Mol Sci)
Status: Published. Computer-modeling and expression study of KE and EW dipeptides; describes thymalin as a polypeptide extract.
Caveat: Abstract read.
Verified Nov 2, 2026
- Tirzepatide once weekly for the treatment of obesity (N Engl J Med)
Status: Published. Phase 3.
Verified Nov 1, 2026
- Immune enhancement in predicted severe acute necrotising pancreatitis: randomised trial (Intensive Care Med)
Status: Published. 508 patients; infected necrosis 15.7% vs 18.1%, p = 0.48.
Caveat: Abstract read.
Verified Nov 1, 2026
- Clinical usefulness of the GHRP-2 test for hypothalamic-pituitary disorder (J Endocr Soc)
Status: Published. Diagnostic test study.
Caveat: Title only.
Verified Nov 1, 2026
- FDA approval record: Mounjaro (NDA 215866)
Status: Approved. Original approval May 13, 2022 per Drugs@FDA.
Verified Nov 1, 2026
- Blood indicators in severe COVID-19 during tocilizumab and thymalin treatment (Adv Gerontol)
Status: Published. Three groups; hospital mortality 40.9% (standard), 28.4% (tocilizumab), 20.6% (thymalin).
Caveat: Abstract read. Randomization and blinding not described.
Verified Nov 2, 2026
- Safety profile of bremelanotide across the clinical development program (J Womens Health)
Status: Published. 3,500 subjects in 43 studies; nausea 40.0% vs 1.3%; focal hyperpigmentation in more than one-third after up to 16 consecutive daily doses.
Caveat: Abstract read.
Verified Nov 2, 2026
- WADA 2022 Prohibited List, S0: names BPC-157 as an example of non-approved substances
Status: Prohibited. The 2022 list says the non-approved substances class covers many substances including but not limited to BPC-157. S0 already covered any substance without government approval for human therapeutic use, so the 2022 text names it as an example.
Caveat: Only the 2021 and 2022 editions were checked.
Verified Oct 31, 2026
- Selank attenuates aversive signs of morphine withdrawal in rats (Bull Exp Biol Med)
Status: Published. Rats.
Caveat: Title only.
Verified Nov 1, 2026
- WADA 2022 Prohibited List, S2: Thymosin-beta4 and its derivatives e.g. TB-500
Status: Prohibited
Caveat: Only the 2022 edition was checked.
Verified Oct 31, 2026
- Once-weekly cagrilintide for weight management in people with overweight and obesity: phase 2 (Lancet)
Status: Published. Phase 2.
Verified Nov 1, 2026
- Dihexa in APP/PS1 mice (Brain Sci)
Status: Published. Reports restored spatial learning and reduced inflammatory markers in mice.
Caveat: Animal study; abstract only.
Verified Oct 31, 2026
- Warning letter to Advanced Nutriceuticals (Guyer Institute), compounder
Status: Issued. Lists BPC-157 among substances that were not nominated for the 503A bulks list.
Caveat: Found by web search and opened; list of letters may be incomplete. A letter states FDA position at the time, not a court finding.
Verified Oct 31, 2026
- Phase IIb venous leg ulcer trial of topical LL-37, 148 patients (Wound Repair Regen)
Status: Published. No significant overall improvement in healing; post hoc improvement in wounds of at least 10 cm2; well tolerated per authors.
Caveat: Abstract only. PubMed gives no day, so the date shown is approximate.
Verified Oct 31, 2026
- Athira Pharma Form 8-K: ATH-1017 metabolizes into dihexa; dihexa development discontinued
Status: Filed. Company says its candidate is a prodrug that metabolizes into dihexa, a WSU compound it licensed, and that it discontinued dihexa development after 2015.
Caveat: Company claim, not a finding. Athira is now LeonaBio, Inc.
Verified Oct 31, 2026
- Notice of concern on the 2013 dihexa design paper (J Pharmacol Exp Ther)
Status: Published. Notice of concern on PMID 23055539.
Caveat: Notice not read. PubMed gives no day, so the date shown is approximate.
Verified Oct 31, 2026
- Notice of concern on the 2014 dihexa mechanism paper (J Pharmacol Exp Ther)
Status: Published. Notice of concern on PMID 25187433.
Caveat: Notice not read. PubMed gives no day, so the date shown is approximate.
Verified Oct 31, 2026
- Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans (J Appl Physiol)
Status: Published. Randomized exercise study, 30 volunteers; measured levels, not an injection.
Verified Oct 31, 2026
- DSIP and motor function in rats after focal stroke (Molecules)
Status: Published. Animal study, per title.
Caveat: Animal study; title only.
Verified Oct 31, 2026
- Development of cagrilintide, a long-acting amylin analogue (J Med Chem)
Status: Published. Chemistry and preclinical.
Verified Nov 1, 2026
- Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2; N Engl J Med)
Status: Published. Phase 3.
Verified Nov 1, 2026
- FDA approval record: Wegovy (NDA 215256)
Status: Approved. Original approval Jun 4, 2021 per Drugs@FDA.
Verified Nov 1, 2026
- Once-weekly semaglutide in adults with overweight or obesity (STEP 1; N Engl J Med)
Status: Published. Phase 3.
Verified Nov 1, 2026
- Melanotan tanning injection: a rare cause of priapism (Sex Med)
Status: Published. Case report.
Caveat: Case report; title only. PubMed gives no day, so the date shown is approximate.
Verified Oct 31, 2026
- Advances in the detection of growth hormone releasing hormone synthetic analogs (Drug Test Anal)
Status: Published. Doping detection.
Caveat: Title only.
Verified Nov 1, 2026
- Re-analyzing phase III bremelanotide trials for HSDD in women (J Sex Res)
Status: Published. Single-author meta-analysis using FDA application data; reports 72.72% of protocol-listed outcomes unreported and adverse-event discontinuation OR 11.98; concludes the drug is generally not useful.
Caveat: Abstract read. One author's view; a published commentary disputes it (PMID 33835907).
Verified Nov 2, 2026
- Warning letter to Predator Nutrition (supplement seller)
Status: Issued. A product labeled to contain BPC-157 was among those FDA said were marketed with claims to mitigate, prevent or treat disease. Issued by FDA food center.
Caveat: Found by web search and opened; list of letters may be incomplete. A letter states FDA position at the time, not a court finding.
Verified Oct 31, 2026
- Warning letter to Tailor Made Compounding LLC naming GHK-Cu among 22 substances
Status: Issued. Compounding pharmacy inspection. FDA says drugs made from the listed bulk substances were not eligible for the 503A exemptions.
Caveat: Found by web search and read directly. List of letters may be incomplete. A warning letter is about the firm, not a finding about the substance.
Verified Oct 31, 2026
- Warning letter to Tailor Made Compounding LLC naming Melanotan II among 22 substances
Status: Issued. Compounding pharmacy inspection. FDA says drugs made from the listed bulk substances were not eligible for the 503A exemptions.
Caveat: Found by web search and read directly. List of letters may be incomplete. A warning letter is about the firm, not a finding about the substance.
Verified Oct 31, 2026
- Warning letter to Tailor Made Compounding LLC naming PEG-MGF among 22 substances
Status: Issued. Compounding pharmacy inspection. FDA says drugs made from the listed bulk substances were not eligible for the 503A exemptions.
Caveat: Found by web search and read directly. List of letters may be incomplete. A warning letter is about the firm, not a finding about the substance.
Verified Oct 31, 2026
- FDA warning letter to Tailor Made Compounding LLC naming CJC 1295 among 22 substances
Status: Warning letter. FDA says drugs compounded from the listed bulk substances were not eligible for the 503A exemptions.
Caveat: A statement about one firm's conduct, not a finding about the substance.
Verified Nov 1, 2026
- Warning letter to Tailor Made Compounding LLC naming LL-37 among 22 substances
Status: Issued. Compounding pharmacy inspection. FDA says drugs made from the listed bulk substances were not eligible for the 503A exemptions.
Caveat: Found by web search and read directly. List of letters may be incomplete. A warning letter is about the firm, not a finding about the substance.
Verified Oct 31, 2026
- Warning letter to Tailor Made Compounding LLC naming DSIP among 22 substances
Status: Issued. Compounding pharmacy inspection. FDA says drugs made from the listed bulk substances were not eligible for the 503A exemptions.
Caveat: Found by web search and read directly. List of letters may be incomplete. A warning letter is about the firm, not a finding about the substance.
Verified Oct 31, 2026
- Warning letter to Tailor Made Compounding LLC naming Epitalon among 22 substances
Status: Issued. Compounding pharmacy inspection. FDA says drugs made from the listed bulk substances were not eligible for the 503A exemptions.
Caveat: Found by web search and read directly. List of letters may be incomplete. A warning letter is about the firm, not a finding about the substance.
Verified Oct 31, 2026
- Warning letter to Tailor Made Compounding LLC naming Semax among 22 substances
Status: Issued. Compounding pharmacy inspection. FDA says drugs made from the listed bulk substances were not eligible for the 503A exemptions.
Caveat: Found by web search and read directly. List of letters may be incomplete. A warning letter is about the firm, not a finding about the substance.
Verified Oct 31, 2026
- FDA warning letter to Tailor Made Compounding LLC naming Ipamorelin among 22 substances
Status: Warning letter. FDA says drugs compounded from the listed bulk substances were not eligible for the 503A exemptions.
Caveat: A statement about one firm's conduct, not a finding about the substance.
Verified Nov 1, 2026
- FDA warning letter to Tailor Made Compounding LLC naming Selank among 22 substances
Status: Warning letter. FDA says drugs compounded from the listed bulk substances were not eligible for the 503A exemptions.
Caveat: A statement about one firm's conduct, not a finding about the substance.
Verified Nov 1, 2026
- FDA warning letter to Tailor Made Compounding LLC naming GHRP-2 among 22 substances
Status: Warning letter. FDA says drugs compounded from the listed bulk substances were not eligible for the 503A exemptions.
Caveat: A statement about one firm's conduct, not a finding about the substance.
Verified Nov 1, 2026
- FDA warning letter to Tailor Made Compounding LLC naming AOD 9604 among 22 substances
Status: Warning letter. FDA says drugs compounded from the listed bulk substances were not eligible for the 503A exemptions.
Caveat: A statement about one firm's conduct, not a finding about the substance.
Verified Nov 1, 2026
- FDA warning letter to Tailor Made Compounding LLC naming GHRP-6 among 22 substances
Status: Warning letter. FDA says drugs compounded from the listed bulk substances were not eligible for the 503A exemptions.
Caveat: A statement about one firm's conduct, not a finding about the substance.
Verified Nov 1, 2026
- Warning letter to Tailor Made Compounding (compounding pharmacy)
Status: Issued. Investigators noted the pharmacy compounded products using BPC 157, among many other peptides.
Caveat: Found by web search and opened; list of letters may be incomplete. A letter states FDA position at the time, not a court finding.
Verified Oct 31, 2026
- FDA warning letter to Tailor Made Compounding LLC: recall of compounded tesamorelin
Status: Warning letter. Acknowledges a voluntary recall of tesamorelin products made Jul 6 to Sep 11, 2018 for an incorrect beyond-use date on vial labels.
Caveat: A statement about one firm's conduct.
Verified Nov 1, 2026
- FDA warning letter to Tailor Made Compounding LLC naming Bremelanotide (PT-141) among 22 substances
Status: Warning letter. FDA says drugs compounded from the listed bulk substances were not eligible for the 503A exemptions.
Caveat: A statement about one firm's conduct, not a finding about the substance.
Verified Nov 2, 2026
- The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations (Drug Test Anal)
Status: Published. Semax found in seized preparations; authors say it has not completed clinical trials.
Verified Oct 31, 2026
- Putative cognitive enhancing research peptides in seized pharmaceutical preparations (Drug Test Anal)
Status: Published. Seized products.
Caveat: Title only.
Verified Nov 1, 2026
- Thymalin: activation of differentiation of human hematopoietic stem cells (Bull Exp Biol Med)
Status: Published. Cell study; CD28 expression up 6.8 times.
Caveat: Abstract read. Laboratory study.
Verified Nov 2, 2026
- Long-term safety and efficacy of bremelanotide for HSDD (Obstet Gynecol)
Status: Published. 52-week open-label extension; 684 enrolled, 272 completed; nausea 40.4%, flushing 20.6%, headache 12.0%.
Caveat: Abstract read. Manufacturer-sponsored.
Verified Nov 2, 2026
- Phase 2 LL-37 cream on diabetic foot ulcers (Universitas Indonesia)
Status: Status unknown. Planned 40 participants. No results posted.
Caveat: Registry entry is sponsor-written. Start date is estimated and given only as Oct 2019.
Verified Oct 31, 2026
- Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials (Obstet Gynecol)
Status: Published. 1,267 women randomized to 1.75 mg as needed or placebo for 24 weeks; desire +0.35 and distress -0.33 versus placebo (integrated); nausea, flushing, headache in 10% or more.
Caveat: Abstract read. Manufacturer-sponsored.
Verified Nov 2, 2026
- FDA approval record: Rybelsus (NDA 213051)
Status: Approved. Original approval Sep 20, 2019 per Drugs@FDA.
Verified Nov 1, 2026
- Warning letter to PD Labs (compounding pharmacy)
Status: Issued. Cites compounding with BPC-157 acetate, notes it was not nominated for the 503A bulks list, and records the firm saying it would continue to compound it.
Caveat: Found by web search and opened; list of letters may be incomplete. A letter states FDA position at the time, not a court finding.
Verified Oct 31, 2026
- Drugs@FDA: Vyleesi (bremelanotide), NDA 210557
Status: Approved. Original approval Jun 21, 2019 per openFDA. Labeling supplements on Oct 23, 2020 and Oct 22, 2026.
Caveat: Read through openFDA, not FDA's own site.
Verified Nov 2, 2026
- Melanotan-induced priapism: a hard-earned tan (BMJ Case Rep)
Status: Published. Case report with review.
Caveat: Case report; title only.
Verified Oct 31, 2026
- Effects of tesamorelin on non-alcoholic fatty liver disease in HIV (Lancet HIV)
Status: Published. Randomised trial, 12 months. Off-label use.
Caveat: Abstract read.
Verified Nov 1, 2026
- Age-dependent changes in responsiveness to kisspeptin-10 in healthy men (Andrologia)
Status: Published. Single 1 microgram/kg bolus; LH rose in all age groups.
Caveat: Abstract read.
Verified Nov 1, 2026
- Identification of a glycine analogue of GHRP-2 in a seized injection vial (Drug Test Anal)
Status: Published. Doping control.
Caveat: Title only.
Verified Nov 1, 2026
- The efficacy of semax in the treatment of patients at different stages of ischemic stroke (Zh Nevrol Psikhiatr)
Status: Published. 110 patients; BDNF and recovery measures.
Caveat: Russian journal; English abstract only.
Verified Oct 31, 2026
- Growth hormone secretagogues: safety and efficacy review (Sex Med Rev)
Status: Published. Few long-term controlled studies; appear well tolerated, with some concern for raised blood glucose.
Caveat: Abstract read.
Verified Nov 2, 2026
- Oral ghrelin receptor agonist MK-0677 increases IGF-1 in hemodialysis patients (Nephrol Dial Transplant)
Status: Published. 26 enrolled, 22 completed; IGF-1 geometric mean 1.07-fold greater.
Caveat: Abstract read.
Verified Nov 1, 2026
- FDA approval record: Ozempic (NDA 209637)
Status: Approved. Original approval Dec 5, 2017 per Drugs@FDA.
Verified Nov 1, 2026
- Detection and in vitro metabolism of confiscated BPC 157 and MGF R23H (Drug Test Anal)
Status: Published. Detection study of a variant found in confiscated vials.
Caveat: Detection study, not a study of PEG-MGF; abstract only. PubMed gives no day, so the date shown is approximate.
Verified Oct 31, 2026
- FDA debarment order after a federal conviction connected to sale of Melanotan II (81 FR 79501)
Status: Issued. Permanent debarment of the owner of a company that sold Melanotan II, after a 2015 conviction on two conspiracy counts. Describes Melanotan II as an unapproved new drug marketed as an injectable tanning product.
Caveat: Individual not named here. A debarment order is about a person, not a finding about the substance.
Verified Oct 31, 2026
- Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6; N Engl J Med)
Status: Published. Phase 3.
Verified Nov 1, 2026
- SciClone Pharmaceuticals 10-K for 2015: ZADAXIN (thymalfasin) approved in over 30 countries
Status: Company filing. Says ZADAXIN is approved in over 30 countries, principally for hepatitis B and as an immune system enhancer; China about 96% of sales; worldwide sales above $146 million in 2015.
Caveat: The company describing its own product; approvals not checked country by country.
Verified Nov 1, 2026
- Phase 1 oral BPC-157 tablets in healthy volunteers (PharmaCotherapia)
Status: Status unknown. Planned 42 volunteers in Tijuana; last verified Oct 2015; no results.
Caveat: Month of posting approximate.
Verified Oct 31, 2026
- Phase 1/2 intratumoral injections of LL37 for melanoma (M.D. Anderson Cancer Center)
Status: Completed. Four participants, starting dose 250 micrograms per tumor weekly for up to 8 weeks. Results posted.
Caveat: Registry entry is sponsor-written. Date shown is the study start date.
Verified Oct 31, 2026
- Vesugen and pinealon in elderly patients with polymorbidity and organic brain syndrome (Adv Gerontol)
Status: Published. 32 people aged 41 to 83; authors report effects on biological age indicators and recommend the peptides as geroprotectors.
Caveat: Abstract read. No control group described.
Verified Nov 2, 2026
- Intra-articular injection of AOD9604 with or without hyaluronic acid in a rabbit osteoarthritis model (Ann Clin Lab Sci)
Status: Published. Rabbits.
Caveat: Title only.
Verified Nov 1, 2026
- Metabolism of ipamorelin and hexarelin after nasal administration, for doping control (Drug Test Anal)
Status: Published. One volunteer per compound; hexarelin metabolite detected after parent compound cleared.
Caveat: Abstract read.
Verified Nov 2, 2026
- Optimization of anxiety-disorder treatment with selank (Zh Nevrol Psikhiatr Im S S Korsakova)
Status: Published. 30 patients on phenazepam versus 40 on selank plus phenazepam.
Caveat: Abstract read.
Verified Nov 1, 2026
- Detection of GHRP-2 and GHRP-6 in urine samples from athletes (Drug Test Anal)
Status: Published. Doping detection.
Caveat: Title only.
Verified Nov 1, 2026
- Dihexa and the HGF/c-Met system (J Pharmacol Exp Ther)
Status: Published. Reports dihexa binds HGF and that its effects depend on HGF/c-Met.
Caveat: RETRACTED (notice Apr 2025); notice of concern Sep 2021. Reason not read. Abstract only. PubMed gives no day, so the date shown is approximate.
Verified Oct 31, 2026
- Ghrelin mimetic ipamorelin for postoperative ileus after bowel resection: phase 2 (Int J Colorectal Dis)
Status: Published. No significant difference from placebo on key efficacy analyses.
Caveat: Abstract read.
Verified Nov 1, 2026
- Anxiolytic effect and tolerability of selank and phenazepam in anxiety disorders (Zh Nevrol Psikhiatr Im S S Korsakova)
Status: Published. 60 patients; authors report anxiolytic and mild nootropic effects.
Caveat: Abstract read; no blinding described.
Verified Nov 1, 2026
- Melanoma associated with the use of melanotan-II (Dermatology)
Status: Published. Case of melanoma in a 20-year-old woman who injected it and used sunbeds.
Caveat: Case report; temporal association, not proof of cause. Abstract only. PubMed gives no day or month, so the date shown is approximate.
Verified Oct 31, 2026
- Melanotan and the posterior reversible encephalopathy syndrome (Ann Intern Med)
Status: Published. Case report letter.
Caveat: Case report; no abstract in PubMed.
Verified Oct 31, 2026
- Calzada Limited ASX announcement: AOD9604 important clarifications
Status: Company filing. Says six human trials in 925 patients, 2001 to 2007, did not show a clinically meaningful weight loss outcome across the total trial population, and that the obesity program was terminated in February 2007. Also describes a 2012 GRAS recognition.
Caveat: Company statement, not an independent review. No per-trial results. The GRAS description is internally inconsistent (conditional in one place, unconditional in another) and does not name FDA.
Verified Nov 1, 2026
- FDA determination that GEREF (sermorelin acetate) was not withdrawn from sale for reasons of safety or effectiveness
Status: Determination. Says EMD Serono notified FDA in 2008 that GEREF products were being discontinued; FDA reviewed the evidence, including postmarketing adverse events, and found they were not withdrawn for safety or effectiveness.
Caveat: Full text read from the govinfo PDF. The notice does not state the company's reason for discontinuing.
Verified Nov 1, 2026
- Drugs@FDA: oxytocin injection (Hikma), ANDA 200219
Status: Approved. Original approval Feb 13, 2013 per openFDA.
Caveat: Read through openFDA, not FDA's own site.
Verified Nov 2, 2026
- Efficacy of thymosin alpha 1 for severe sepsis (ETASS): multicenter randomized trial (Crit Care)
Status: Published. 361 patients; 28-day mortality 26.0% vs 35.0%, p = 0.062 non-stratified.
Caveat: Abstract read.
Verified Nov 1, 2026
- Design of dihexa from angiotensin IV analogs (J Pharmacol Exp Ther)
Status: Published. Reports an orally active, blood-brain-barrier-permeant analog with antidementia-type effects in lab tests.
Caveat: Carries a Sep 2021 notice of concern; abstract only. PubMed gives no day, so the date shown is approximate.
Verified Oct 31, 2026
- Peptide neuroprotectors in older adults, including pinealon (Adv Gerontol)
Status: Published. Review.
Caveat: Abstract read.
Verified Nov 2, 2026
- Melanotan II injection resulting in systemic toxicity and rhabdomyolysis (Clin Toxicol (Phila))
Status: Published. Case report.
Caveat: Case report; title only. PubMed gives no day, so the date shown is approximate.
Verified Oct 31, 2026
- Amidated MGF analogues identified in black-market products (Rapid Commun Mass Spectrom)
Status: Published. Mass spectrometry of two black-market preparations.
Caveat: Detection study, not a study of PEG-MGF; abstract only.
Verified Oct 31, 2026
- Pinealon in rat offspring with hyperhomocysteinemia (Int J Clin Exp Med)
Status: Published. Rat study; improved spatial learning in offspring.
Caveat: Abstract read. Animal study.
Verified Nov 2, 2026
- MK-0677 for patients recovering from hip fracture: randomized, placebo-controlled trial (Arch Gerontol Geriatr)
Status: Published. 123 patients; terminated early due to a safety signal of congestive heart failure in a limited number of patients.
Caveat: Abstract read. FDA does not cite a source; wording matches.
Verified Nov 1, 2026
- Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men (J Clin Endocrinol Metab)
Status: Published. Dose-dependent LH rise; peak at 1 microgram/kg.
Caveat: Abstract read.
Verified Nov 1, 2026
- Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy (Drugs)
Status: Published. Review.
Caveat: Title only.
Verified Nov 1, 2026
- Pinealon in cell cultures: reactive oxygen species and cell cycle (Rejuvenation Res)
Status: Published. Cell study.
Caveat: Abstract read. Laboratory study.
Verified Nov 2, 2026
- Drugs@FDA: Egrifta (tesamorelin acetate), BLA 022505
Status: Approved. Original approval Nov 10, 2010 (new molecular entity) per openFDA.
Caveat: Read through openFDA, not FDA's own site.
Verified Nov 1, 2026
- Thymosin alpha 1, interferon alfa, or both with dacarbazine in metastatic melanoma (J Clin Oncol)
Status: Published. 488 patients; survival differences not significant.
Caveat: Abstract read.
Verified Nov 1, 2026
- RLS drug encyclopedia: Timalin (thymus extract), registration LS-000267
Status: Registered (Russia). Registration of Feb 26, 2010, holder Samson-Med, freeze-dried powder 10 mg; shows reissue under Eurasian Economic Union rules and a validity date of Dec 18, 2027.
Caveat: Read through the RLS aggregator, not the state register (GRLS). Page has no indications section. Page is in Russian.
Verified Nov 2, 2026
- Tesamorelin in HIV-infected patients with excess abdominal fat: pooled analysis of two phase 3 trials (J Clin Endocrinol Metab)
Status: Published. 806 patients, 26 weeks plus 26-week extension.
Caveat: Abstract read.
Verified Nov 1, 2026
- Diagnosis of adrenal insufficiency using the GHRP6 test versus the insulin tolerance test (Horm Metab Res)
Status: Published. 49 patients and 20 controls.
Caveat: Abstract read.
Verified Nov 1, 2026
- Activation of the GH/IGF-1 axis by CJC-1295 results in serum protein profile changes in normal adult subjects (Growth Horm IGF Res)
Status: Published. Healthy adults.
Caveat: Title and journal details only.
Verified Nov 1, 2026
- From lab to bedside: emerging clinical applications of thymosin alpha 1 (Expert Opin Biol Ther)
Status: Published. Review; reports approval in over 35 countries.
Caveat: Abstract read; approval list not verified.
Verified Nov 1, 2026
- Oral ghrelin mimetic MK-677 in healthy older adults: randomized trial (Ann Intern Med)
Status: Published. 65 adults, two years. Fat-free mass +1.1 kg vs -0.5 kg; fasting glucose up; insulin sensitivity down.
Caveat: Abstract read.
Verified Nov 1, 2026
- Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease (Inflamm Bowel Dis)
Status: Published. Mouse colitis models.
Caveat: Animal study.
Verified Oct 31, 2026
- Long-term safety and effects of tesamorelin in HIV patients with abdominal fat accumulation (AIDS)
Status: Published. 26-week extension phase.
Caveat: Abstract read.
Verified Nov 1, 2026
- MK-677: no clinical effect on Alzheimer disease progression in a randomized trial (Neurology)
Status: Published. Title reports no clinical effect.
Caveat: Title only.
Verified Nov 1, 2026
- PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation (Gastroenterology)
Status: Published. Lab and cell transporter study.
Caveat: Not a human study.
Verified Oct 31, 2026
- Metabolic effects of a growth hormone-releasing factor in patients with HIV (N Engl J Med)
Status: Published. 412 patients; visceral fat -15.2% vs +5.0%.
Caveat: Abstract read.
Verified Nov 1, 2026
- Pulsatile GH secretion persists during continuous stimulation by CJC-1295 (J Clin Endocrinol Metab)
Status: Published. Healthy adults.
Caveat: Title and journal details only.
Verified Nov 1, 2026
- Metabolic Pharmaceuticals release: first 100 subjects complete the AOD9604 phase 2b obesity trial
Status: Company release. 536 enrolled; oral 0.25, 0.5 and 1 mg versus placebo; 12-week primary endpoint; results expected March 2007.
Caveat: A company release with no results. We found no results announcement.
Verified Nov 1, 2026
- Randomized trial of GHK-Cu skin care after CO2 laser resurfacing (Arch Facial Plast Surg)
Status: Published. 13 patients completed it. No significant difference in erythema; questionnaire favored GHK-Cu for overall skin quality (P = .04).
Caveat: Small trial; abstract only. PubMed gives no day, so the date shown is approximate.
Verified Oct 31, 2026
- Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults (J Clin Endocrinol Metab)
Status: Published. Healthy adults.
Caveat: Title and journal details only; funding not checked.
Verified Nov 1, 2026
- Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? (Clin Interv Aging)
Status: Published. Title only.
Caveat: Title only; no abstract on PubMed.
Verified Nov 1, 2026
- GHRP-6 for the prevention of multiple organ failure (Clin Sci)
Status: Published. Cell lines and a rat ischaemia model; not a human study.
Caveat: Abstract read.
Verified Nov 1, 2026
- GPR54 and kisspeptin in reproduction (Hum Reprod Update)
Status: Published. Review.
Caveat: Title only.
Verified Nov 1, 2026
- hGRF(1-29)-albumin bioconjugates activate the GRF receptor in rats; identification of CJC-1295 as a long-lasting GRF analog (Endocrinology)
Status: Published. First description of the compound; rats.
Caveat: Animal study.
Verified Nov 1, 2026
- Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males (J Clin Endocrinol Metab)
Status: Published. Six men; LH, FSH and testosterone higher than with saline.
Caveat: Abstract read. Kisspeptin-54, not -10.
Verified Nov 1, 2026
- News report: successful trial for phase 2B fat burner (AOD9604 phase 2 obesity results)
Status: News report. Says the trial enrolled 300 obese patients at five sites for 12 weeks in six oral groups (0, 1, 5, 10, 20, 30 mg). Reports an average 2.8 kg loss at 1 mg against 0.8 kg on placebo. No other dose results and no p-values.
Caveat: News article; does not say where its figures come from. Read through a summarizing fetch.
Verified Nov 2, 2026
- News report: Metabolic Pharmaceuticals defends AOD9604 phase 2 obesity results
Status: News report. Reports 1 mg and 30 mg doses, a mean 2.8 kg weight change at 1 mg and a primary-analysis p-value of 0.1 against placebo; analysts questioned the results.
Caveat: A news report relaying company statements; no group sizes or duration given. Trial report not found.
Verified Nov 1, 2026
- AOD-9604 Metabolic (Curr Opin Investig Drugs)
Status: Published. Pipeline note: phase IIa trials underway by Feb 2002.
Caveat: Abstract read.
Verified Nov 1, 2026
- Pralmorelin: GHRP 2, KP-102 (Drugs R D)
Status: Published. Drug profile; diagnostic agent for growth hormone deficiency.
Caveat: Abstract read.
Verified Nov 1, 2026
- Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa (Neuro Endocrinol Lett)
Status: Published. Abstract reports a 90% positive effect; no group sizes given.
Caveat: Small study from one research group; abstract only.
Verified Oct 31, 2026
- Geroprotective effect of thymalin and epithalamin (Adv Gerontol)
Status: Published. 266 elderly people followed 6 to 8 years; authors report fewer respiratory illnesses and lower mortality than a control group.
Caveat: Abstract read. Authors from the institute that developed these peptides; assignment to groups not described.
Verified Nov 2, 2026
- GHRP-2, TRH and GnRH in men with prolonged critical illness (Clin Endocrinol)
Status: Published. 33 men; randomized infusion.
Caveat: Abstract read; no deaths attributed to GHRP-2 in the abstract.
Verified Nov 1, 2026
- BPC peptide salts with organo-protective activity, the process for their preparation and their use in therapy
Status: Granted US patent (current legal status not checked). Original BPC filing family. Priority May 23, 1997, filed May 20, 1998. Inventor Predrag Sikiric, who also authors many of the BPC-157 papers in PubMed. The family was filed in more than 20 jurisdictions.
Caveat: A 1998 filing would normally expire about 20 years after filing; each family member was not checked. A patent shows what an owner claims, not that a product works or is safe.
Verified Oct 31, 2026
- Ipamorelin counteracts glucocorticoid-induced decrease in bone formation in adult rats (Growth Horm IGF Res)
Status: Published. Rats.
Caveat: Animal study; title only.
Verified Nov 1, 2026
- Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment (Int J Obes)
Status: Published. Mice.
Caveat: Title only.
Verified Nov 1, 2026
- Melanotan II in men with organic erectile dysfunction (Urology)
Status: Published. 4 of 19 injections associated with severe nausea.
Caveat: Small crossover study; abstract only.
Verified Oct 31, 2026
- Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers (Pharm Res)
Status: Published. Healthy men; half-life about 2 hours.
Caveat: Abstract read.
Verified Nov 1, 2026
- Hexarelin and recombinant growth hormone in healthy men: hormone and cardiac effects (J Endocrinol Invest)
Status: Published. Seven male volunteers; same GH rise; hexarelin raised cortisol and LV ejection fraction (70.7% vs 64.0%); no BP or heart rate change.
Caveat: Abstract read.
Verified Nov 2, 2026
- Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency (BioDrugs)
Status: Published. Test of GH reserve; limited data on daily injection in some prepubertal children.
Caveat: Abstract read.
Verified Nov 1, 2026
- GHRP-2 plus TRH infusion in prolonged critical illness (J Clin Endocrinol Metab)
Status: Published. 14 patients; randomized crossover infusion.
Caveat: Abstract read; no deaths attributed to GHRP-2 in the abstract.
Verified Nov 1, 2026
- Melanotan-II in men with psychogenic erectile dysfunction (J Urol)
Status: Published. Erections in 8 of 10 men; nausea, stretching, yawning more frequent than placebo.
Caveat: Small crossover study; abstract only. PubMed gives no day, so the date shown is approximate.
Verified Oct 31, 2026
- Open clinical trial of DSIP in opioid detoxification (J Clin Psychopharmacol)
Status: Published. Title read only.
Caveat: Letter; title only, no abstract read. PubMed gives no day, so the date shown is approximate.
Verified Oct 31, 2026
- MK-677 reverses diet-induced catabolism (J Clin Endocrinol Metab)
Status: Published. Eight healthy volunteers, crossover.
Caveat: Abstract read.
Verified Nov 1, 2026
- Drugs@FDA: GEREF (sermorelin acetate) 0.5 mg and 1.0 mg per vial, NDA 020443
Status: Discontinued. Original approval Sep 26, 1997 per openFDA.
Caveat: Read through openFDA, not FDA's own site.
Verified Nov 1, 2026
- Growth hormone-releasing peptides (Eur J Endocrinol)
Status: Published. Review of synthetic GHRPs and their receptor.
Caveat: Abstract read.
Verified Nov 1, 2026
- Effectiveness of semax in acute period of hemispheric ischemic stroke (Zh Nevrol Psikhiatr)
Status: Published. 30 Semax patients vs 80 controls.
Caveat: Russian journal; English abstract only.
Verified Oct 31, 2026
- Phase I pilot study of melanotan-II in 3 healthy men (Life Sci)
Status: Published. Somnolence, nausea, spontaneous erections and increased pigmentation reported.
Caveat: Very small; abstract only. PubMed gives no day or month, so the date shown is approximate.
Verified Oct 31, 2026
- GHRP-6 test in the diagnosis of GH deficiency (J Pediatr Endocrinol Metab)
Status: Published. Responses overlapped between deficient and normal children; near-absent in pituitary stalk transection.
Caveat: Abstract read.
Verified Nov 1, 2026
- Double-blind study of DSIP in 16 chronic insomniacs (Neuropsychobiology)
Status: Published. Authors say effects were weak and short-term treatment is not likely to be of major benefit.
Caveat: Small; abstract only. PubMed gives no day or month, so the date shown is approximate.
Verified Oct 31, 2026
- Drugs@FDA: GEREF (sermorelin acetate) 0.05 mg per ampule, NDA 019863
Status: Discontinued. Original approval Dec 28, 1990 per openFDA.
Caveat: Read through openFDA, not FDA's own site.
Verified Nov 1, 2026
- Placebo-controlled study of DSIP in 14 chronic insomniacs (Eur Neurol)
Status: Published. Authors report improved night sleep and daytime performance over 7 nights.
Caveat: Small, 1987; abstract only. PubMed gives no day or month, so the date shown is approximate.
Verified Oct 31, 2026
- DSIP in the treatment of withdrawal syndromes from alcohol and opiates (Eur Neurol)
Status: Published. Title read only.
Caveat: Title only, no abstract read. PubMed gives no day or month, so the date shown is approximate.
Verified Oct 31, 2026
- Drugs@FDA: Pitocin (oxytocin), NDA 018261
Status: Approved. Original approval Nov 19, 1980 per openFDA.
Caveat: Read through openFDA, not FDA's own site.
Verified Nov 2, 2026
- Drugs@FDA: oxytocin injection (Fresenius Kabi), NDA 018248
Status: Approved. Original approval Jul 9, 1980 per openFDA.
Caveat: Read through openFDA, not FDA's own site.
Verified Nov 2, 2026
- Phase 2 CJC-1295 study in HIV patients with visceral obesity (ConjuChem)
Status: Terminated. Placebo-controlled, 12 weeks. Terminated; Dec 2005 to Sep 2006.
Caveat: Registry gives no reason. FDA's 2024 briefing cites a participant's death.
Verified Nov 1, 2026
- Merck phase 2: MK-0677 for sarcopenia in patients after hip fracture (0677-032)
Status: Terminated. 83 enrolled; terminated Sep 2005 to Aug 2007. No reason stated.
Caveat: Registry record opened.
Verified Nov 1, 2026
- Phase 2: LUM-201 (ibutamoren mesylate) in nonalcoholic fatty liver disease (Massachusetts General Hospital)
Status: Completed. 12 enrolled; completed Dec 2024; results posted.
Caveat: Results not read.
Verified Nov 1, 2026
- Phase 3: LUM-201 in children with growth hormone deficiency (Lumos Pharma)
Status: Recruiting. 150 planned; recruiting; started May 20, 2026; estimated completion Jan 2028.
Caveat: Registry names the drug LUM-201 only.
Verified Nov 1, 2026
- Phase 2 ipamorelin versus placebo for recovery of GI function (Helsinn)
Status: Completed. 320 enrolled. Completed May 2014. No results posted; no publication found.
Caveat: No publication found by us.
Verified Nov 1, 2026
- STEP 1: semaglutide in people with overweight or obesity
Status: Completed. Novo Nordisk. Completed; completion Mar 2021.
Verified Nov 1, 2026
- Phase 2: prolonged pulsatile kisspeptin in hypogonadotropic hypogonadism (Seminara)
Status: Completed. Completed Aug 2025; results posted.
Caveat: Results not read.
Verified Nov 1, 2026
- Phase 1: kisspeptin administration in the adult (Massachusetts General Hospital)
Status: Completed. Completed Oct 2021. No results posted.
Caveat: Registry record opened.
Verified Nov 1, 2026
- Phase 1: kisspeptin in the evaluation of delayed puberty (MGH)
Status: Completed. Completed Sep 2021. No results posted.
Caveat: Registry record opened.
Verified Nov 1, 2026
- Phase 1: kisspeptin to quantify GnRH neuronal function in health and disease (Seminara)
Status: Recruiting. Recruiting; estimated completion May 2030.
Caveat: Registry record opened.
Verified Nov 1, 2026
- Ozempic prescribing information, including boxed warning on thyroid C-cell tumors
Status: Current label. Boxed warning: risk of thyroid C-cell tumors seen in rodents; unknown in humans.
Caveat: Label read on Nov 1, 2026.
Verified Nov 1, 2026
- Mounjaro prescribing information
Status: Current label. Uses: type 2 diabetes in adults and children 10 and older; reduce major cardiovascular events in adults with type 2 diabetes at high risk.
Caveat: Label read on Nov 1, 2026.
Verified Nov 1, 2026
- CagriSema compared with tirzepatide in obesity
Status: Completed. Novo Nordisk. Completed; completion listed Jan 2026.
Verified Nov 1, 2026
- REDEFINE 3: CagriSema in people with heart and vascular disease
Status: Active, not recruiting. Novo Nordisk. Active, not recruiting; completion listed Oct 2027.
Verified Nov 1, 2026
- Pre-approval expanded access of retatrutide (LY3437943)
Status: Available. Eli Lilly. Listed as available.
Verified Nov 1, 2026
- Phase 3 retatrutide in obesity or overweight with knee osteoarthritis (TRIUMPH-4 per Lilly)
Status: Completed. Eli Lilly. Completed; completion listed Nov 2025.
Verified Nov 1, 2026
- Intravenous safety pilot in two adults (Lee and Burgess, Altern Ther Health Med)
Status: Published Sept 2025. Two adults received up to 20 mg by infusion. No change in the tested blood markers and no side effects reported. Authors call for further studies.
Caveat: Two participants, no placebo. Both had received intravenous BPC-157 before. The abstract does not say where the BPC-157 came from. Full text not read.
Verified Oct 31, 2026
- PMDA drug database entry: GHRP Kaken 100 Injection (pralmorelin hydrochloride), package insert revised July 2025
Status: Listed (Japan). Prescription-only; indication is diagnosis of growth hormone secretion deficiency. Package insert revised July 2025 (third edition; previous revision July 2022). Sales start Feb 2005. States no discontinuation and gives no current sales status.
Caveat: Page is in Japanese; we read it through a summarizing fetch. Does not show whether the product is on sale today.
Verified Nov 2, 2026
- Tirzepatide in obstructive sleep apnea and obesity (master protocol)
Status: Completed. Eli Lilly. Completed; completion Mar 2024.
Verified Nov 1, 2026
- Phase 3 retatrutide in obesity with cardiovascular disease (TRIUMPH-3 per Lilly)
Status: Completed. Eli Lilly. Completed; completion listed May 2026.
Verified Nov 1, 2026
- Phase 3 retatrutide in adults with obesity or overweight (TRIUMPH-1 per Lilly)
Status: Completed. Eli Lilly. Completed; completion listed Apr 2026.
Verified Nov 1, 2026
- Interstitial cystitis pilot study (Lee, Walker and Ayadi, Altern Ther Health Med)
Status: Published Oct 2024. 12 women whose previous drug had failed got a single 10 mg injection around the bladder lesion during a cystoscopy. All reported symptom relief on a questionnaire; no adverse events were reported.
Caveat: No control group. Compounding pharmacy product used. Same first author and journal as the 2025 IV report. Full text not read.
Verified Oct 31, 2026
- Tirzepatide compared with dulaglutide on major cardiovascular events in type 2 diabetes (SURPASS-CVOT)
Status: Completed. Eli Lilly. Completed; completion Jun 2025.
Verified Nov 1, 2026
- RECONNECT study 301: bremelanotide in premenopausal women with HSDD (phase 3)
Status: Completed. 723 enrolled per registry; completed Jun 2017; results posted.
Caveat: Registry enrollment differs from the 1,267 randomized in the published paper; not reconciled.
Verified Nov 2, 2026
- RECONNECT study 302: bremelanotide in premenopausal women with HSDD (phase 3)
Status: Completed. 714 enrolled per registry; completed Jun 2017; results posted.
Caveat: Registry record opened.
Verified Nov 2, 2026
- Phase 2: bremelanotide in premenopausal women with female sexual arousal disorder and/or HSDD
Status: Completed. 612 enrolled; completed Sep 2012; results posted.
Caveat: Results not read.
Verified Nov 2, 2026
- Phase 2: bremelanotide co-administered with tirzepatide for obesity
Status: Active, not recruiting. 108 estimated; active, not recruiting. Registry estimated completion (Mar 31, 2025) has passed.
Caveat: Registry record opened.
Verified Nov 2, 2026
- Phase 4: single dose of Vyleesi in lactating women (breast milk concentration)
Status: Completed. 10 enrolled; completed Nov 15, 2025. No results posted.
Caveat: Registry record opened.
Verified Nov 2, 2026
- Tirzepatide on morbidity and mortality in adults with obesity
Status: Active, not recruiting. Eli Lilly. Active, not recruiting; completion listed Oct 2027.
Verified Nov 1, 2026
- Merck phase 2: MK-0677 in Alzheimer's disease
Status: Completed. Completed 2006. No results posted.
Caveat: Registry record opened.
Verified Nov 1, 2026
- Phase 2: thymalfasin for COVID-19 (Rhode Island Hospital)
Status: Terminated. Terminated.
Verified Nov 1, 2026
- Phase 3: thymosin alpha-1 with peginterferon alfa-2a and ribavirin (sigma-tau)
Status: Completed. Completed.
Verified Nov 1, 2026
- Phase 3: thymosin plus peginterferon in hepatitis C with cirrhosis, prior nonresponders (SciClone)
Status: Completed. Completed.
Verified Nov 1, 2026
- Phase 2 ipamorelin for postoperative ileus (Helsinn)
Status: Completed. 117 enrolled. Completed Dec 2009. Published 2014.
Verified Nov 1, 2026
- Zepbound prescribing information, including boxed warning on thyroid C-cell tumors
Status: Current label. Boxed warning: risk of thyroid C-cell tumors seen in rats; unknown in humans. Uses: weight management; obstructive sleep apnea in adults with obesity.
Caveat: Label read on Nov 1, 2026.
Verified Nov 1, 2026
- Holland & Knight: FDA advisory committee endorses compounding of certain peptides
Status: Law firm summary. Reports the July 23-24 committee recommended BPC-157 for the compounding list, with emideltide the exception among the peptides reviewed. The vote is nonbinding.
Caveat: Secondary source. Vote tallies were not available in the sources read. Automated access was blocked in the latest check; the summary comes from the dossier earlier read.
Verified Oct 31, 2026
- WADA 2021 Prohibited List (does not name BPC-157)
Status: Not named. The 2021 list does not name BPC-157.
Caveat: Included for comparison with 2022.
Verified Oct 31, 2026
Records are added when we verify them against the primary source. A record here is not an endorsement of what it says. Missing items are listed on each dossier under “Still not covered.”